Document:

<Page>

CONFIDENTIAL TREATMENT REQUESTED                                   EXHIBIT 10.11

CONFIDENTIAL TREATMENT REQUESTED: PAGES WHERE CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED ARE MARKED "CONFIDENTIAL TREATMENT REQUESTED" AND APPROPRIATE
SECTIONS, WHERE TEXT HAS BEEN OMITTED, ARE NOTED WITH "[CONFIDENTIAL TREATMENT
REQUESTED]." AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                SUPPLY AGREEMENT

                                     BETWEEN

                        CATALYTICA PHARMACEUTICALS, INC.

                                       AND

                        IDEC PHARMACEUTICALS CORPORATION

<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                                SUPPLY AGREEMENT

       THIS SUPPLY AGREEMENT is made effective as of this ____ day of August,
2001, by and between IDEC PHARMACEUTICALS CORPORATION, a corporation organized
under the laws of the State of Delaware and having a place of business at 3030
Callan Road, San Diego, California 92121 ("Customer") and CATALYTICA
PHARMACEUTICALS, INC., a corporation organized under the laws of the State of
Delaware and having a place of business at US 13/NC 11, Greenville, North
Carolina 27834 ("Catalytica") (each individually a "Party" and collectively the
"Parties").

                                   WITNESSETH:

       WHEREAS, Customer wishes to distribute commercially a certain
pharmaceutical product known as ibritumomab tiuxetan ("Zevalin") in finished
dosage form for human use;

       WHEREAS, Catalytica has the experience, personnel, facilities, and
expertise necessary to perform chemical and pharmaceutical development,
manufacturing, packaging, analytical testing and quality assurance services for
the manufacturing, labeling and packaging of such product for sale to Customer;

       WHEREAS, Customer desires Catalytica to perform such services and sell
such product to Customer and Catalytica desires to perform such services and
sell such product to Customer, all on the terms and conditions set forth in this
Agreement;

       WHEREAS, the Parties desire to negotiate in good faith to attempt to
achieve a broader strategic alliance with respect to the commercialization of
Zevalin; and

       NOW, THEREFORE, in consideration of the mutual covenants and promises set
forth herein, the Parties agree as follows:

                                    ARTICLE 1
                                   DEFINITIONS

       The following terms, whether used in the singular or plural, shall have
the meanings assigned to them below for purposes of this Agreement:

       1.1   "ACQUISITION COST" shall mean the actual invoiced price paid by
either Party to any Third Party for acquiring IDEC Ingredients or Excipients
hereunder, including, but not limited to, shipping and handling costs and
customs duties incurred and paid by such Party to any Third Party in connection
with the acquisition of IDEC Ingredients or Excipients, as the case may be.

       1.2   "IDEC INGREDIENTS" shall mean, with respect to the Product,
[CONFIDENTIAL TREATMENT REQUESTED].

                                        2
<Page>

                                                          CONFIDENTIAL TREATMENT

       1.3   "AFFILIATE" shall mean any corporation or non-corporate entity
which directly or indirectly controls, is controlled by, or is under common
control with a Party. A corporation or non-corporate entity shall be regarded as
in control of another corporation if it owns or directly or indirectly controls
at least fifty percent (50%) of the voting stock of the other corporation or (a)
in the absence of the ownership of at least fifty percent (50%) of the voting
stock of a corporation or (b) in the case of a non-corporate entity, the power
to direct or cause the direction of the management and policies of such
corporation or non-corporate entity, as applicable.

       1.4   "AGREEMENT" shall mean this Supply Agreement, including any
exhibits, supplements and modifications approved in writing by appropriate
corporate officers of each of the Parties.

       1.5   "APPLICABLE LAWS AND REGULATIONS" shall mean all federal, state,
and local laws, regulations and guidelines of the United States or the European
Union ("EU") that apply to the services being provided by Catalytica under this
Agreement, including, without limitation, the requirements of the U.S. Food and
Drug Administration and other United States and EU governmental authorities
which may be applicable, as such requirements may be amended from time to time,
as well as those laws, regulations and guidelines of any other jurisdiction
mutually agreed by the Parties in a supplement hereto.

       1.6   "BATCH" shall mean any of the following: (a) a development/clinical
trial batch of Product; (b) a Validation Batch; or (c) with respect to Product,
either (i) a specifically defined batch or (ii) any other size batch as agreed
to by Catalytica and Customer, as applicable.

       1.7   "CONFIDENTIAL INFORMATION" shall mean all information, data,
know-how and all other business, technical and financial data disclosed
hereunder by one Party or any of its Affiliates to the other Party or any of its
Affiliates, except any portion thereof which:

       (a)   at the time of disclosure, is the subject of the public knowledge;

       (b)   after disclosure, becomes part of the public knowledge by
publication or otherwise, except by breach of this Agreement by the recipient;

       (c)   the recipient can demonstrate by its written records that were in
the recipient's possession at the time of such disclosure, and which was not
acquired, directly or indirectly, from the disclosing party;

       (d)   was lawfully disclosed to the recipient on a non-confidential basis
by a Third Party who is not obligated to the disclosing Party or any other Third
Party to retain such Confidential Information in confidence;

       (e)   results from research and development by the recipient independent
of such disclosure as shown by competent written evidence; or

       (f)   is required to be disclosed by legal process; PROVIDED, in each
case the Party so disclosing information timely informs the other Party and uses
its best efforts to limit the disclosure and maintain confidentiality to the
extent possible and permits the other Party to attempt by appropriate legal
means to limit such disclosure.
                                        3
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

       Written Confidential Information shall be identified by the disclosing
Party as being confidential by stamping the cover pages of such information
"Confidential." Confidential Information disclosed orally, visually and/or in
another tangible form shall be identified by the disclosing Party to the
receiving Party as confidential at the time of such disclosure and confirmed to
the receiving Party within thirty (30) days after such disclosure in a writing
marked "Confidential."

       1.8   "CONTRACT QUARTER" shall mean each period of three (3) successive
calendar months during each Contract Year, the first Contract Quarter commencing
on the first day of the first Contract Year.

       1.9   "CONTRACT YEAR" shall mean the period of twelve (12) successive
calendar months commencing on the first day of the month of the first Delivery
Date, PROVIDED that the first Delivery Date shall be [CONFIDENTIAL TREATMENT
REQUESTED], and each successive twelve (12) month period thereafter.

       1.10   "COORDINATOR" OR "COORDINATORS" shall mean that authorized
representative and backup representative appointed respectively by Customer and
Catalytica hereunder who shall be responsible for the exchange of all
communications of proprietary and non-proprietary information other than legal
notices and activities covered by the Quality Agreement (as defined below),
related to the manufacturing, testing, labeling and packaging of the Product.

       1.11   "CURRENT GOOD MANUFACTURING PRACTICES OR cGMP" shall mean current
Good Manufacturing Practice regulations, directives, and guidelines established
by: (i) regulations promulgated under the Federal Food, Drug and Cosmetic Act,
including 21 C.F.R. Parts 210 and 211 and 600, and (ii) the Guide to
Manufacturing Practice for Medicinal Products under European Directives, as all
of such regulations, guidelines and directives may be amended from time to time.

       1.12   "CUSTOMER'S BLA" shall mean Customer's biologics license
application ("BLA") relating to the formulation of the Product or any
amendments, and any supplements to such BLA as may be filed during the term
hereof.

       1.13   "DELIVERY DATE" shall mean a date for which delivery of Product is
stated in a Purchase Order.

       1.14   "DRUG PRODUCT COMPONENT SPECIFICATIONS" shall mean the
specifications for the IDEC Ingredients and Excipients (collectively, the "Drug
Product Components") which will be attached hereto as Exhibit 2 and made a part
hereof, as determined in accordance with the analytical methodology set forth
therein, as such specifications may be amended from time to time by mutual
agreement of the Parties.

       1.15   "EFFECTIVE DATE" shall mean the date appearing at the beginning of
this Agreement.

       1.16   "EXCIPIENTS" shall mean the raw materials, other than IDEC
Ingredients, required to manufacture the Product in accordance with the Product
Specifications.

                                        4
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

       1.17   "FACILITY" shall mean Catalytica's SPO-South production facility
located at the intersection of US 13 and NC 11 with US 264 By-Pass in
Greenville, North Carolina or such other manufacturing facilities mutually
agreed upon in writing by the Parties.

       1.18   "FD&C ACT" shall mean the United States Federal Food, Drug and
Cosmetic Act, as amended.

       1.19   "FDA" shall mean the United States Food and Drug Administration,
or any successor entity.

       1.20   "FIRST COMMERCIAL SALE" shall mean the first commercial sale of
the Commercial Drug Product by Customer or its Affiliates in the Territory
following Product Approval.

       1.21   "INITIAL TERM" shall have the meaning set forth in Section 10.1
hereof.

       1.22   "KIT" shall mean a Labeled Kit or an Unlabeled Kit.

       1.23   "LABELED KIT" shall mean [CONFIDENTIAL TREATMENT REQUESTED]. The
term "Kit component" shall mean any [CONFIDENTIAL TREATMENT REQUESTED].

       1.24   "LABELED IMAGING KIT" shall mean [CONFIDENTIAL TREATMENT
REQUESTED].

       1.25   "LABELED THERAPEUTIC KIT" shall mean [CONFIDENTIAL TREATMENT
REQUESTED].

       1.26   "MATERIAL SUPPLY FAILURE" shall mean: [CONFIDENTIAL TREATMENT
REQUESTED].

       1.27   "PACKAGING SPECIFICATIONS" shall mean the packaging and labeling
specifications for the Product which will be attached hereto as Exhibit 3 and
made a part hereof, as such specifications may be amended from time to time by
mutual agreement of the Parties.

                                        5
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

       1.28   "PARTIAL BATCH" shall mean that portion of a Batch of Product
which is less than all of any specifically defined Batch or less than all of
any other size Batch as agreed to by Catalytica and Customer, as applicable.

       1.29   "PRODUCT" shall mean the [CONFIDENTIAL TREATMENT REQUESTED].

       1.30   "PRODUCT APPROVAL" shall mean (i) final approval of Customer's
BLA by the FDA with respect to Product to be marketed in the United States; (ii)
final approval of all applicable authorities of the EU as well as its component
countries if so required, of all filings necessary with respect to Product to be
marketed in the EU; or (iii) as to any other country or jurisdiction mutually
agreed by the Parties, approval by any national, supra national, regional, state
or local regulatory agency, department, bureau, commission, council or other
governmental entity, necessary for the lawful manufacture, distribution, use,
import, export or sale of such Product in such country.

       1.31   "PRODUCT PRICE" shall mean the price set forth in Exhibit 1
attached hereto and made a part hereof, as such price may be amended from time
to time during the Initial Term or any renewal term.

       1.32   "PRODUCT SPECIFICATIONS" shall mean the specifications for the
Product which are attached hereto as Exhibit 4 and made a part hereof, as such
specifications may be amended from time to time by mutual written agreement of
the Parties, including without limitation such amendments as may be required to
obtain Product Approval.

       1.33   "PURCHASE ORDER" shall have the meaning set forth in Section 7.1
hereof.

       1.34   "QUALITY AGREEMENT" shall mean the Intercompany Quality Agreement,
as further defined in Section 5.5, and attached hereto as Exhibit 5 as well as
any amendments and/or any addendum thereto or any separate intercompany quality
agreement entered into pursuant to SECTION 5.6 hereof.

       1.35   "SECONDARY PACKAGING COMPONENTS" shall mean packaging components
other than vials, stoppers and aluminum caps.

       1.36   "SPECIFICATIONS" shall mean the Product Specifications and the
Packaging Specifications.

       1.37   "TERRITORY" shall mean the United States of America.

       1.38   "THIRD PARTY" shall mean any party other than Customer, Catalytica
and their respective Affiliates.

       1.39   "UNLABELED KIT" shall mean [CONFIDENTIAL TREATMENT REQUESTED].

                                        6
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

       1.40   "VALIDATION ACTIVITIES" shall mean those activities, as required
by cGMP, that shall be performed by Catalytica prior to the First Commercial
Sale including, but not limited to, qualification of facilities, laboratories,
equipment, computers and utilities, process qualification, qualification of
physical and analytical test methods, preparation of validation technical
reports, cleaning validation, and manufacturing of Validation Batches.

       1.41   "VALIDATION BATCHES" for a dosage form shall mean those batches
manufactured by Catalytica during the course of the Validation Activities.

                                    ARTICLE 2
                          SALE AND PURCHASE OF PRODUCT

       2.1   [CONFIDENTIAL TREATMENT REQUESTED].

       2.2   DEVELOPMENT/CLINICAL TRIALS PRODUCT. Catalytica agrees to supply
sufficient quantities of Product as requested by Customer for pre-clinical
activities and clinical trials or other developmental activities in accordance
with the prices set forth in Exhibit 1 hereto, subject to adjustment as set
forth in Section 8.2 hereof. Any such quantities of Product purchased by
Customer from Validation Batches shall be included in the calculation of
[CONFIDENTIAL TREATMENT REQUESTED] Kits.

       2.3   [CONFIDENTIAL TREATMENT REQUESTED].

       (a)   ADVERSE REGULATORY ACTION. [CONFIDENTIAL TREATMENT REQUESTED]

       (b)   BUSINESS INTERRUPTION INSURANCE. Customer shall attempt to obtain
business interruption insurance relative to Catalytica's production of Product,
which business interruption insurance shall be substantially similar to that
obtained by Customer in respect of other transactions of this magnitude and
shall be satisfactory to Customer in its sole discretion. [CONFIDENTIAL
TREATMENT REQUESTED]

       (c)   [CONFIDENTIAL TREATMENT REQUESTED]

       (d)   [CONFIDENTIAL TREATMENT REQUESTED]

                                    ARTICLE 3
                                  COORDINATORS

       Within ten (10) days after the Effective Date hereof, Customer and
Catalytica shall each appoint an authorized representative and a backup
representative ("Coordinators") who will be responsible for the exchange of all
communications of proprietary and non-proprietary information other than legal
notices and activities covered by the Quality Agreement (as defined in Section
5.6 hereof), related to the manufacturing, testing, labeling and packaging of
the Product. Each such Party shall provide notice to the other Party as to the
name and title of the individuals so appointed. Each Party may replace its
Coordinators with qualified personnel at any time for any reason by providing
written notice to the other Party in accordance with Section 19.10 hereof. The
Coordinators shall conduct quarterly meetings in person or by such other

                                        7
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

means as the Parties may so agree, to review project progress, any developments
regarding appropriate inventory levels, manufacturing, testing, labeling, or
packaging of Product, including cGMP compliance matters, and efforts to expedite
the quality assurance/quality control process. The Coordinators shall negotiate
in good faith to reach agreement as to all such matters. A written report of
meetings shall be prepared on an alternating basis by the assigned Coordinator
of each of the Parties and promptly distributed to the Coordinator for the other
Party hereto.

                                   ARTICLE 4
                EQUIPMENT; IDEC INGREDIENTS; EXCIPIENTS; ARTWORK

       4.1   EQUIPMENT. Catalytica shall be responsible for purchasing,
installing, and qualifying at its facility any and all appropriate new or used
dedicated equipment, molds, and tooling necessary for the manufacturing,
packaging, and labeling of the Product, provided that [CONFIDENTIAL TREATMENT
REQUESTED] Catalytica shall be responsible for scheduling and performing routine
maintenance, calibration, and servicing of such equipment so long as such
equipment remains at Catalytica's facility. Catalytica shall maintain
appropriate written records of such maintenance and service activities as
required by all Applicable Laws and Regulations, together with a current
inventory of all equipment [CONFIDENTIAL TREATMENT REQUESTED] Notwithstanding
the forgoing, in the event that Catalytica purchases used equipment as provided
hereunder, Catalytica shall obtain from the seller of such used equipment,
sufficient documentation to demonstrate that any and all product residuals have
been removed or obliterated. In the event that Catalytica determines that it is
necessary to purchase equipment previously used in the manufacture of
antibiotics, cytotoxics or other sensitizing compounds, such purchase shall
occur [CONFIDENTIAL TREATMENT REQUESTED].

       4.2   IDEC INGREDIENTS SUPPLY. As soon as possible after submitting each
Purchase Order for Product [CONFIDENTIAL TREATMENT REQUESTED], Customer shall
provide to Catalytica sufficient quantities of IDEC Ingredients, [CONFIDENTIAL
TREATMENT REQUESTED], necessary for Catalytica to manufacture Product hereunder,
as well as applicable certificates of analysis. In the event Customer is unable
to provide such IDEC Ingredients [CONFIDENTIAL TREATMENT REQUESTED]. Upon
request by Catalytica, Customer shall promptly send Catalytica all reference
standards relating to the IDEC Ingredients developed by or for Customer.
Customer shall ensure that all imported IDEC Ingredients or other materials
supplied to Catalytica by or on behalf of Customer comply with all applicable
laws and regulations relating to the import of such IDEC Ingredients and
materials and receive all required governmental and regulatory approvals,
including without limitation customs and FDA approvals. Catalytica shall receive
the IDEC Ingredients and use product tracking, identification and inventory
procedures in accordance with all Applicable Laws and Regulations.

       4.3   TITLE TO IDEC INGREDIENTS SUPPLIED BY CUSTOMER. Customer shall
retain title to all IDEC Ingredients and accompanying documentation supplied to
Catalytica.

                                        8
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

       4.4   EXCIPIENTS SUPPLY. Catalytica shall, [CONFIDENTIAL TREATMENT
REQUESTED], supply Excipients for the Product as well as all other materials
required to manufacture, test, package, label and release the Product, with the
exception of IDEC Ingredients.

       4.5   ARTWORK. [CONFIDENTIAL TREATMENT REQUESTED], Customer shall provide
at no cost to Catalytica, in a format mutually agreed upon by the Parties,
digital artwork for all packaging components to be used in the manufacture of
the Product, which artwork shall meet the Packaging Specifications.
Notwithstanding the foregoing, the Parties shall cooperate and use their best
commercial efforts to finalize and expeditiously utilize for packaging any
artwork needed for the initial commercialization of the Product.

                                   ARTICLE 5
                  WARRANTIES; SPECIFICATIONS; QUALITY AGREEMENT

       5.1   WARRANTIES BY CATALYTICA.

       (a)   Catalytica warrants to Customer that the Product prior to and at
the time of sale and shipment by Catalytica, (1) will conform to the
Specifications, as then in effect, (2) will have been formulated, manufactured,
stored, tested, labeled and shipped in accordance with cGMP, and all Applicable
Laws and Regulations, and as set forth in the Certificate of Compliance and
Certificate of Analysis for such Product (provided in accordance with the
Quality Agreement) and (3) will not be (i) adulterated or misbranded by
Catalytica within the meaning of the FD&C Act, or (ii) an article that may not
be introduced into interstate commerce under the provisions of Sections 404 or
505 of the FD&C Act, or (iii) an article that fails to comply with all
Applicable Laws and Regulations.

       (b)   Catalytica warrants that the Facility has been adequately designed,
qualified and maintained, and that Catalytica has appropriate licenses, permits
and authorizations, including without limitation a CBER facility license, from
applicable federal, state and local authorities such that Catalytica may carry
out its obligations under this Agreement. Catalytica further warrants that it
has an adequate number of employees with requisite training, education and
experience required by cGMP, and that all persons performing the services under
this Agreement have not been debarred under section 306 of the FD&C Act, and
that it is in compliance with all Applicable Laws and Regulations. Catalytica
further represents and warrants that to the best of its knowledge the
performance of its services hereunder will not infringe any patent or other
intellectual property right of any Third Party.

       5.2   DISCLAIMER BY CATALYTICA. [CONFIDENTIAL TREATMENT REQUESTED]

       5.3   WARRANTIES BY CUSTOMER. Customer warrants that, at the time it
releases or causes to be released the IDEC Ingredients to Catalytica for use in
the manufacture of the Product, the IDEC Ingredients shall meet the Drug Product
Component Specifications and shall be suitable for use in the manufacture of the
Product. Customer warrants that upon delivery to Catalytica, no IDEC Ingredients
constituting or being part of any shipment or other delivery now or hereafter
made to Catalytica will be adulterated or misbranded within the meaning of the
FD&C Act or would be an article which may not be introduced into interstate
commerce under the

                                        9
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

provisions of Section 404 or 505 of the FD&C Act. Catalytica shall have no
responsibility for, or liability with respect to, any Product that fails to
comply with the warranties set forth in Section 5.1 hereof (i) due in whole or
in part to the failure of any IDEC Ingredient to comply with the warranties set
forth in this Section 5.3 or (ii) to the extent impacted or affected by IDEC's
negligence or willful misconduct or IDEC's breach of this Agreement. In the
event Customer ships Product outside of the United States, Customer represents
and warrants that it will comply fully with all export administration and
control laws and regulations of the United States government as may be
applicable to the export, resale or other disposition of any Products purchased
from Catalytica.

       5.4   SHELF LIFE. The Parties warrant and covenant that they shall
cooperate and use commercially reasonable efforts to expedite the quality
assurance/quality control process to increase the shelf life of Product with
respect to those portions of the process controlled by each of the respective
Parties. The Parties shall cooperate and work together in good faith to evaluate
and implement changes to the Agreement needed to address difficulties associated
with increasing shelf life of Product in light of regulatory adjustments to
shelf life, provided, however, Catalytica shall provide Customer with Product
which shall have at least the Minimum Shelf Life. [CONFIDENTIAL TREATMENT
REQUESTED].

       5.5   SPECIFICATION OR SCOPE CHANGES. In the event Customer changes the
Specifications, Customer shall promptly advise Catalytica in writing of such
changes, and if such changes are acceptable to Catalytica, Catalytica shall
promptly advise Customer as to any scheduling and/or price adjustments which may
result from such changes. The Parties shall cooperate and shall make a good
faith effort to implement any required changes. In the event Customer requests a
change in the scope of this Agreement, Catalytica agrees to give good faith
consideration to implementation of such scope change. Prior to implementation of
such specification or scope changes, [CONFIDENTIAL TREATMENT REQUESTED]
Specification changes will be handled by the change control procedures set forth
in the Quality Agreement. Customer agrees to reimburse Catalytica for the
reasonable expenses incurred by Catalytica as a result of such specification and
scope changes, [CONFIDENTIAL TREATMENT REQUESTED]. If during the term of this
Agreement Customer amends or is required by law to amend the Specifications so
as to render the IDEC Ingredients, Excipients and/or packaging components for
the Product obsolete, Customer shall purchase from Catalytica [CONFIDENTIAL
TREATMENT REQUESTED] that amount of inventory of Excipients and packaging
components so rendered obsolete, and Customer shall purchase from Catalytica
[CONFIDENTIAL TREATMENT REQUESTED] that amount of inventory of Product so
rendered obsolete, but only to the extent that such inventory has been purchased
pursuant to agreement of the Coordinators as described below and in Article 3
hereof. The Parties shall discuss the inventory levels of packaging components,
other materials (including IDEC Ingredients and Excipients), and Product at each
quarterly meeting of the Coordinators, as described in Article 3 hereof, in
order to establish financially reasonable levels of inventories and/or
procedures for purchasing and holding components, materials and Product.

       5.6   QUALITY AGREEMENT. Catalytica and Customer have entered into a
mutually acceptable Quality Agreement, a true and correct copy is attached
hereto as Exhibit 5, to further detail the quality control and the quality
assurance obligations and responsibilities of the Parties

                                       10
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

with respect to the manufacture of Product to be sold in the Territory ("Quality
Agreement"). [CONFIDENTIAL TREATMENT REQUESTED].

                                   ARTICLE 6
                                FORECASTS; ORDERS

       6.1   FORECAST SCHEDULES.

       (a)   [CONFIDENTIAL TREATMENT REQUESTED] NON-BINDING FORECAST.
[CONFIDENTIAL TREATMENT REQUESTED], Customer shall deliver to Catalytica
[CONFIDENTIAL TREATMENT REQUESTED], a non-binding forecast of Customer's
potential purchases of Product from Catalytica hereunder ("Non-Binding
Forecast"). Such Non-Binding Forecast shall be for the sole purpose of
permitting Catalytica and Customer to plan scale-up activities and future
purchases of capital equipment and components that may be required to fulfill
such forecasts and shall not constitute an obligation of Customer to purchase
the quantities of Product indicated in such forecasts. On or before each annual
anniversary date of the Effective Date, Customer shall deliver to Catalytica an
updated Non-Binding Forecast [CONFIDENTIAL TREATMENT REQUESTED].

       (b)   ROLLING [CONFIDENTIAL TREATMENT REQUESTED] FORECASTS.

             (i)   ROLLING [CONFIDENTIAL TREATMENT REQUESTED] FORECAST. Customer
       shall provide Catalytica with a "Rolling [CONFIDENTIAL TREATMENT
       REQUESTED] Forecast" as provided herein. Customer shall provide the first
       Rolling [CONFIDENTIAL TREATMENT REQUESTED] Forecast [CONFIDENTIAL
       TREATMENT REQUESTED]. Customer shall update such Rolling [CONFIDENTIAL
       TREATMENT REQUESTED] Forecast monthly.

             (ii)   FIRM ORDERS. [CONFIDENTIAL TREATMENT REQUESTED] shall be
       considered "Firm Orders," against which Catalytica shall institute
       production and Customer is required to submit Purchase Orders. Firm
       Orders shall specify Delivery Dates for the Kits of Product included
       therein, and each such Delivery Date shall, when initially provided for a
       Firm Order, allow Catalytica [CONFIDENTIAL TREATMENT REQUESTED] in which
       to fill such Firm Order. The cumulative Firm Order Kit quantities
       included within each [CONFIDENTIAL TREATMENT REQUESTED] Firm Order period
       shall be one hundred percent (100%) binding on both Parties,
       [CONFIDENTIAL TREATMENT REQUESTED].

             (iii)   SEMI-FIRM ORDERS. The [CONFIDENTIAL TREATMENT REQUESTED]
       shall be considered "Semi-Firm Orders". For each [CONFIDENTIAL TREATMENT
       REQUESTED] period of a Rolling [CONFIDENTIAL TREATMENT REQUESTED]
       Forecast set forth below, [CONFIDENTIAL TREATMENT REQUESTED] Forecast.
       Notwithstanding the foregoing, during the first Contract Year, Customer
       shall not be bound to the [CONFIDENTIAL TREATMENT REQUESTED]. For each
       [CONFIDENTIAL TREATMENT REQUESTED] period of a Rolling [CONFIDENTIAL
       TREATMENT REQUESTED] forecast [CONFIDENTIAL TREATMENT REQUESTED].

                                       11
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

<Table>
         <S>                <C>                 <C>
         TIME PERIOD        [CONFIDENTIAL       [CONFIDENTIAL
                            TREATMENT           TREATMENT
                            REQUESTED]          REQUESTED]

         [CONFIDENTIAL      [CONFIDENTIAL       [CONFIDENTIAL
         TREATMENT          TREATMENT           TREATMENT
         REQUESTED]         REQUESTED]          REQUESTED]

         [CONFIDENTIAL      [CONFIDENTIAL       [CONFIDENTIAL
         TREATMENT          TREATMENT           TREATMENT
         REQUESTED]         REQUESTED]          REQUESTED]

         [CONFIDENTIAL      [CONFIDENTIAL       [CONFIDENTIAL
         TREATMENT          TREATMENT           TREATMENT
         REQUESTED]         REQUESTED]          REQUESTED]
</Table>

       For each [CONFIDENTIAL TREATMENT REQUESTED] period of a Rolling
[CONFIDENTIAL TREATMENT REQUESTED] Forecast, the Product quantity obligations
set forth above shall be binding as a cumulative Kit quantity over such
[CONFIDENTIAL TREATMENT REQUESTED].

             (iv)   CONFIRMATION OF FIRM ORDERS. Within [CONFIDENTIAL TREATMENT
       REQUESTED] after receiving the initial and each update for the Rolling
       [CONFIDENTIAL TREATMENT REQUESTED] Forecast, Catalytica shall provide
       Customer written confirmation of Catalytica's ability to meet the Firm
       Order quantities included within such Rolling [CONFIDENTIAL TREATMENT
       REQUESTED] Forecast. In addition, Catalytica shall provide Customer the
       scheduled dates or approximate dates of the runs for the [CONFIDENTIAL
       TREATMENT REQUESTED] covered by such Rolling [CONFIDENTIAL TREATMENT
       REQUESTED] Forecast.

             (v)   Customer shall use reasonable efforts to forecast Product
       needs on a reasonably uniform basis throughout each Contract Year.
       [CONFIDENTIAL TREATMENT REQUESTED]

       (c)   ROLLING [CONFIDENTIAL TREATMENT REQUESTED] OPERATIONS SCHEDULE.
Customer and Catalytica shall collaborate in good faith to maintain an ongoing
"Rolling [CONFIDENTIAL TREATMENT REQUESTED] Operations Schedule", which shall be
provided by Catalytica on a monthly basis commencing [CONFIDENTIAL TREATMENT
REQUESTED] and shall cover a period of approximately [CONFIDENTIAL TREATMENT
REQUESTED]. The Rolling [CONFIDENTIAL TREATMENT REQUESTED] Operations Schedule
shall include (i) dates or approximate dates on which Customer shall ship IDEC
Ingredients to Catalytica, (ii) size or approximate size of IDEC Ingredients;
(iii) dates or approximate dates on which Catalytica will manufacture and fill
Batches of Product, (iv) dates or approximate dates for Customer release of
Product, (v) scheduled dates or approximate dates upon which Kits or Kit
components shall be labeled, (vi) size or approximate size of Kits of Product,
(vii) dates or approximate dates upon which Kits or

                                       12
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

Unlabelled Kit components will be packaged and shipped, (viii) destination for
shipment of Kits of Product and (ix) current inventory schedules for each Kit
component. The Rolling [CONFIDENTIAL TREATMENT REQUESTED] Operations Schedule
shall be used by the Parties for planning and coordination, and the Parties
shall communicate and cooperate in good faith to ensure that such document is as
accurate and up-to-date as possible.

       (d)   NOTIFICATIONS REGARDING [CONFIDENTIAL TREATMENT REQUESTED] AND
[CONFIDENTIAL TREATMENT REQUESTED]. The Parties shall use good faith to
determine the [CONFIDENTIAL TREATMENT REQUESTED] and [CONFIDENTIAL TREATMENT
REQUESTED] obligations applicable to particular periods under Section (b) (ii)
and (b) (iii) above. If either Party hereto determines that the other Party may
breach an obligation related to the [CONFIDENTIAL TREATMENT REQUESTED] or
[CONFIDENTIAL TREATMENT REQUESTED] the Party who makes such determination shall
notify the other Party as soon as reasonably practicable. The Party who is
believed to be in danger of breaching its obligation hereunder shall be provided
a reasonable opportunity to correct its forecast, schedule, or other intended
course of action so that it may avoid such breach, and the other Party hereto
shall use reasonable efforts to allow and accommodate such correction. In the
event that the Parties disagree on the calculation of the [CONFIDENTIAL
TREATMENT REQUESTED] or [CONFIDENTIAL TREATMENT REQUESTED] applicable to
[CONFIDENTIAL TREATMENT REQUESTED] time period, the Parties shall negotiate in
good faith to resolve any such disagreement.

       6.2   [CONFIDENTIAL TREATMENT REQUESTED]

       (a)   [CONFIDENTIAL TREATMENT REQUESTED].

             (i)   In the event that Customer does not meet its [CONFIDENTIAL
       TREATMENT REQUESTED] for a particular [CONFIDENTIAL TREATMENT REQUESTED]
       period, [CONFIDENTIAL TREATMENT REQUESTED], provided, however, that
       Customer shall receive a credit for components purchased during such
       [CONFIDENTIAL TREATMENT REQUESTED] period in accordance with Section 7.
       Each Kit of Product shall be valued at [CONFIDENTIAL TREATMENT
       REQUESTED]. Catalytica shall, within [CONFIDENTIAL TREATMENT REQUESTED]
       following the end of each [CONFIDENTIAL TREATMENT REQUESTED] Firm Order
       period, invoice Customer for any amounts owed under this Section
       6.2(a)(i). Customer shall pay such invoice within [CONFIDENTIAL TREATMENT
       REQUESTED] of the date of receipt thereof. If Customer has been given
       credit for the purchase of any Kits or Kit components during any
       [CONFIDENTIAL TREATMENT REQUESTED] period, such credit shall be
       applicable to that [CONFIDENTIAL TREATMENT REQUESTED] period.

             (ii)   Notwithstanding the foregoing, Customer may, with
       Catalytica's consent, which shall not be unreasonably withheld,
       substitute another Customer product that has been developed, tested,
       manufactured and marketed by Customer in order to meet the [CONFIDENTIAL
       TREATMENT REQUESTED] hereunder; PROVIDED, HOWEVER, that (A) any such
       substitute product is reasonably comparable to the Product and the timing
       requirements of any substitute Product are practicable, (B) [CONFIDENTIAL

                                       13
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

       TREATMENT REQUESTED], and (C) the Parties shall negotiate in good faith
       to determine (i) that price will be paid to Catalytica for such
       substituted product, and (ii) the extent to which the quantities of
       substituted product shall be deemed to substitute for the Product
       included in Firm Orders and/or Semi-Firm Orders hereunder.

       (b)   [CONFIDENTIAL TREATMENT REQUESTED]. For each relevant [CONFIDENTIAL
TREATMENT REQUESTED] period, Catalytica shall be obligated to supply up to the
[CONFIDENTIAL TREATMENT REQUESTED] of Product, as further described in Section
6.1(b)(ii) and (b) (iii) above. In the event that Customer presents total Firm
Orders or Semi-Firm Orders for Product for a particular [CONFIDENTIAL TREATMENT
REQUESTED] period that exceed the [CONFIDENTIAL TREATMENT REQUESTED] specified
in Section 6.1(b)ii or (b)iii above, Catalytica shall use its commercially
reasonable efforts to supply the excess quantity by adjusting its schedules and
making any other commercially reasonable accommodations. If Catalytica is able
to supply such excess quantity, the parties shall agree in writing on a new
[CONFIDENTIAL TREATMENT REQUESTED] for such time period.

       (c)   BATCH FAILURES. In the event that any run results in nonconforming
Product for which Catalytica bears liability under the Agreement, such failed
Batch shall be counted in determining whether the [CONFIDENTIAL TREATMENT
REQUESTED] has been met hereunder, but such failed Batch shall not be counted in
determining whether the [CONFIDENTIAL TREATMENT REQUESTED] has been exceeded
hereunder.

                                    ARTICLE 7
                         PURCHASE OF PRODUCT; DELIVERIES

       7.1   PURCHASE ORDERS. Except to the extent the Parties may otherwise
agree with respect to a particular shipment, the Product shall be ordered by
Customer pursuant to written purchase orders (a "Purchase Order"), which shall
be sent to Catalytica [CONFIDENTIAL TREATMENT REQUESTED] specified in such
Purchase Orders. [CONFIDENTIAL TREATMENT REQUESTED]. Upon receipt by Catalytica
of each Purchase Order hereunder which conforms in substance and procedure to
the requirements of this Agreement, which Purchase Order may, but is not
required to specify Labeled Kit components by lot number, Catalytica shall
supply and deliver Product in accordance with such Purchase Order and this
Agreement. If such Purchase Order identifies Labeled Kit Components by lot
number, Catalytica shall, [CONFIDENTIAL TREATMENT REQUESTED], notify Customer as
to whether Catalytica agrees with such identification. Notwithstanding
Customer's rights under Section 7.5 hereof, if Catalytica determines that
[CONFIDENTIAL TREATMENT REQUESTED] any requested delivery of Product will be
delayed [CONFIDENTIAL TREATMENT REQUESTED] beyond the Delivery Date set forth in
the Purchase Order, Catalytica shall so advise Customer, and as to any delayed
delivery which results from an Unexcused Failure, Catalytica shall use its best
commercial efforts to deliver the remaining portion of such Purchase Order
quantity as quickly as possible after any such delay. As to each Purchase Order,
if Labeled Kit components have not been identified by lot number, [CONFIDENTIAL
TREATMENT REQUESTED], Catalytica shall identify by lot number proposed Labeled
Kit components to be used in filling such Purchase Order. Customer shall have
the right to approve the proposed components, which approval shall not be
unreasonably

                                       14
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

withheld. Except as specified above, once received by Catalytica, Purchase
Orders are firm and may not be cancelled or modified without Catalytica's prior
consent.

       During the initial Contract Year, in the event that Customer withdraws a
Purchase Order upon [CONFIDENTIAL TREATMENT REQUESTED], Customer shall be
responsible for and shall reimburse Catalytica for [CONFIDENTIAL TREATMENT
REQUESTED]. Customer may withdraw a purchase order upon [CONFIDENTIAL TREATMENT
REQUESTED] and Catalytica in good faith shall use commercially reasonable
efforts to obtain projects or other work for the production time otherwise
specified for Customer's Product. In such event, Customer shall be liable
[CONFIDENTIAL TREATMENT REQUESTED].

       7.2   PURCHASE QUANTITIES. All Product shall be ordered in Labeled Kits
or Unlabeled Kits, or if necessary to meet Customer's other contractual
obligations, individual components. Each Purchase Order shall specify the
quantity of Kits or components being ordered. Quantities actually shipped
pursuant to a given Purchase Order may vary from the quantities reflected in
such Purchase Order [CONFIDENTIAL TREATMENT REQUESTED] and still be deemed to be
in compliance with such Purchase Order; provided, however, Customer shall only
be invoiced and required to pay for the quantities of Product which Catalytica
actually ships to Customer.

       7.3   DELIVERY TERMS. The terms of delivery for the Product shall be
[CONFIDENTIAL TREATMENT REQUESTED] Catalytica's Greenville, North Carolina
plant. Risk of loss and/or damage to the IDEC Ingredients [CONFIDENTIAL
TREATMENT REQUESTED]. Title and risk of loss and/or damage to the Kits or
components [CONFIDENTIAL TREATMENT REQUESTED].

       7.4   SHIPMENT; IMPORT AND EXPORT MATTERS. Catalytica shall ship the
Product in accordance with the Quality Agreement to such designations chosen by
Customer to the extent such shipments are permitted by Applicable Laws and
Regulations related thereto. In the event Customer requests that the Product be
shipped to a third party purchaser, such third party shall have all approvals
under Applicable Laws and Regulations to receive, use and/or sell the Product.
Customer and, as applicable, such third party purchaser will prepare, obtain,
and maintain all necessary import and export registrations relating to the
Product and the IDEC Ingredients. Customer represents and warrants that it will
comply with all applicable import and export laws and regulations. Catalytica
shall cooperate with the Customer by preparing and filing any necessary
documents to support the Customer's import and export applications.

       7.5   MATERIAL SUPPLY FAILURE. In the event of a Material Supply Failure,
Customer shall provide Catalytica written notification of such Material Supply
Failure. Upon Customer's provision of such notice to Catalytica, [CONFIDENTIAL
TREATMENT REQUESTED]

       If a Material Supply Failure occurs during the term of this Agreement,
and subsequent to the occurrence of such Material Supply Failure, [CONFIDENTIAL
TREATMENT REQUESTED]

       7.6   UNBALANCED ORDERING/PRODUCTION. The Parties acknowledge that
Customer may ask Catalytica to produce volumes of different vial sizes or types
of Product and to store such

                                       15
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

vials and/or types for later incorporation into kits or for shipment in another
mutually agreed form. The Parties further acknowledge that Catalytica has
limited storage space for Product, that such storage (and the delay in shipping
Product and receiving payment) has a cost, and that the retention of Product in
storage may change performance obligations. Catalytica shall store Product, if
so requested by Customer, [CONFIDENTIAL TREATMENT REQUESTED]. Pursuant to
Article 3 hereof the Parties shall in good faith establish procedures for
designating Product to be stored by Catalytica, the conditions for such storage
and the responsibilities and liabilities of the Parties as to Product so stored.

                                   ARTICLE 8
                   PRICE; PRICE INCREASES; ADDITIONAL PAYMENTS

       8.1   PRICE. For all Product which is the subject of Purchase Orders
submitted by Customer, Customer shall pay to Catalytica the Product Price set
forth in Exhibit 1 hereto, subject to adjustment as set forth in Sections 8.2
and 8.3 hereof.

       8.2   PRICE INCREASES. The Product Price may be increased [CONFIDENTIAL
TREATMENT REQUESTED]

       8.3   PRICE DECREASES. [CONFIDENTIAL TREATMENT REQUESTED]

       8.4   TAXES. The Product Price set forth in Exhibit 1 does not include
sales, use, consumption, or excise taxes of any taxing authority. The amount of
such taxes, if any, will be [CONFIDENTIAL TREATMENT REQUESTED] at the time of
shipment thereof and [CONFIDENTIAL TREATMENT REQUESTED]. Customer shall pay the
amount of such taxes to Catalytica in accordance with the payment provisions of
this Agreement.

       8.5   ADDITIONAL PAYMENTS. As additional consideration for Catalytica's
performance of its obligations hereunder, Customer shall pay Catalytica the
amounts set forth below (with all payments being due [CONFIDENTIAL TREATMENT
REQUESTED] of receipt of the relevant Catalytica invoice, unless otherwise
provided below). All invoices shall provide reasonable detail of services
performed and costs incurred.

       [CONFIDENTIAL TREATMENT REQUESTED]

       8.6   METHOD OF PAYMENT. At the time of each shipment of Product
hereunder, Catalytica shall invoice Customer, and Customer shall pay for such
Product [CONFIDENTIAL TREATMENT REQUESTED] of receipt of each such invoice. All
payments due hereunder to Catalytica shall be sent to Catalytica by check at the
times set forth herein as Catalytica may designate to Customer from time to time
in accordance with Section 19.10 hereof:

                                       16
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

             Cash Management Coordinator
             Catalytica Pharmaceuticals, Inc.
             Post Office Box 1887
             Greenville, North Carolina  27835-1887
             Facsimile No.:  252-707-3277

       All uncontested amounts not paid when due shall bear interest from the
due date [CONFIDENTIAL TREATMENT REQUESTED], and Customer shall be responsible
for reasonable attorneys' fees and expenses incurred by Catalytica in connection
with the collection thereof.

                                    ARTICLE 9
                                     RECALLS

       Catalytica and Customer each shall notify the other promptly if any Batch
of Product is alleged or proven to be the subject of a recall, market withdrawal
or correction, and Customer shall promptly notify Catalytica of any recall in
any country outside the Territory. The Parties shall cooperate in the handling
and disposition of such recall, market withdrawal or correction including by way
of example exchanging relevant data and, if applicable, relevant data from
IDEC's licensee. In the event of a disagreement as to any matters related to
such recall, market withdrawal or correction, other than the determination of
who shall bear the costs as set forth in the immediately following sentence,
Customer shall have final authority with respect to such matters, as described
in the Quality Agreement. Customer shall bear the cost of all recalls, market
withdrawals or corrections of Product unless such recall, market withdrawal or
correction shall have been the result of Catalytica's negligence, willful
misconduct or breach of this Agreement, in which case Catalytica shall bear the
direct cost of administering such recall, market withdrawal or correction.
[CONFIDENTIAL TREATMENT REQUESTED]. Customer shall maintain records of all sales
of Product and customers sufficient to adequately administer a recall, market
withdrawal or correction for a period of [CONFIDENTIAL TREATMENT REQUESTED]
after termination or expiration of this Agreement. Customer shall in all events
be responsible for interactions with FDA or other governmental authorities that
conduct or request any recalls, market withdrawals or corrections with respect
to the Product.

                                   ARTICLE 10
                                TERM; TERMINATION

       10.1   TERM. Unless sooner terminated pursuant to the terms hereof, the
term of this Agreement shall commence on the Effective Date and shall continue
for a period of [CONFIDENTIAL TREATMENT REQUESTED] (the "Initial Term").

       10.2   TERMINATION BY MUTUAL AGREEMENT. This Agreement may be terminated
at any time upon mutual written agreement between the Parties.

       10.3   TERMINATION FOR PRODUCT WITHDRAWAL OR FAILURE TO OBTAIN PRODUCT
APPROVAL. Customer may terminate this Agreement (i) upon written notice given no
later than [CONFIDENTIAL TREATMENT REQUESTED] after a Product recall under
Article 9 which is wholly or principally caused by Catalytica, or withdrawal of
the Product from the

                                       17
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

Territory caused by order of any applicable regulatory authority; or (ii) if
Customer elects to permanently cease selling the Product in the Territory by
providing written notice to Catalytica at least [CONFIDENTIAL TREATMENT
REQUESTED] prior to the date of such termination; or (iii) immediately if
Customer does not obtain Product Approval on or before [CONFIDENTIAL TREATMENT
REQUESTED] after the Effective Date. Subject to Catalytica's express consent
this Agreement shall be reinstated if Customer resumes sales of Product in the
Territory during the Initial Term hereof.

       10.4   TERMINATION FOR DEFAULT. This Agreement may be terminated by
either Party in the event of the material breach (including without limitation
the occurrence of a Material Supply Failure) or default by the other Party of
the terms and conditions hereof; provided, however, the other Party shall first
give to the defaulting Party written notice of the proposed termination or
cancellation of this Agreement, specifying the grounds therefor. Upon receipt of
such notice, the defaulting Party shall have [CONFIDENTIAL TREATMENT REQUESTED]
to respond by curing such default [CONFIDENTIAL TREATMENT REQUESTED] or
[CONFIDENTIAL TREATMENT REQUESTED] by delivering to the other Party a
certificate that such breach is not capable of being cured within such
[CONFIDENTIAL TREATMENT REQUESTED] and that the breaching Party is working
diligently to cure such breach, but in no event shall the time period for curing
such breach exceed an additional [CONFIDENTIAL TREATMENT REQUESTED], unless
otherwise agreed to in writing by the Parties. If the breaching Party does not
so respond or fails so to work diligently and to cure such breach within the
additional time set forth above, then the other Party may either suspend the
Agreement indefinitely or terminate the Agreement. Termination of this Agreement
pursuant to this Section 10.4 shall not affect any other rights or remedies
which may be available to the nondefaulting Party.

       10.5   TERMINATION FOR FORCE MAJEURE EVENT OR OTHER COURT ORDER OR
INJUNCTION. Customer or Catalytica may terminate this Agreement in the event
Catalytica or Customer are unable to substantially perform their respective
obligations under this Agreement for a period of [CONFIDENTIAL TREATMENT
REQUESTED] due to a Force Majeure Event, by providing written notice to the
other Party at least [CONFIDENTIAL TREATMENT REQUESTED] prior to the date of
such termination, or immediately in the event that any court enters an order,
restraining order, or injunction in respect of, or in any action or proceeding
related to or involving the Catalytica Property or Customer Property (as defined
in Sections 15.1 and 15.2 below), which order or injunction purports to restrain
Customer from selling the Product.

       10.6   BANKRUPTCY; INSOLVENCY. Either Party may terminate this Agreement
upon the occurrence of either of the following:

       (a)   The entry of a decree or order for relief by a court having
jurisdiction in the premises in respect of such Party in an involuntary case
under the Federal Bankruptcy Code, as now constituted or hereafter amended, or
any other applicable federal or state insolvency or other similar law and the
continuance of any such decree or order unstayed and in effect for a period of
[CONFIDENTIAL TREATMENT REQUESTED]; or

                                       18
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

       (b)   The filing by such Party of a petition for relief under the Federal
Bankruptcy Code, as now constituted or hereafter amended, or any other
applicable federal or state insolvency or other similar law.

       (c)   If an order for relief is entered pursuant to any bankruptcy
petition filed by or against Catalytica, to the extent allowed by any and all
Applicable Laws and Regulations, Customer shall have the immediate right to take
possession of any of its equipment, to make copies of all development,
manufacturing, packaging, labeling, storage, testing, distribution and related
records then held by Catalytica, and upon express approval of the applicable
court or administrative body to take possession of samples of any IDEC
Ingredient or Product held for quality control or stability testing.

       10.7   EXPIRATION; TERMINATION; CONSEQUENCES.

       (a)   Upon expiration or termination of this Agreement, whichever is
sooner, [CONFIDENTIAL TREATMENT REQUESTED]

       (b)   In addition, upon expiration or termination of this Agreement,
[CONFIDENTIAL TREATMENT REQUESTED].

       (c)   In the event this Agreement is terminated prior to its expiration,
other than termination by Catalytica pursuant to Section 10.4 hereof, the
[CONFIDENTIAL TREATMENT REQUESTED] set forth in Section 6.1 hereof shall be
reduced proportionately for the Contract Year in which the Agreement is
terminated.

       (d)   In the event this Agreement is terminated or expires, Catalytica
shall make immediately available to the Customer copies of all prior
manufacturing and process development documents and records. Catalytica agrees
to store the originals of such records in a safe and secure facility for at
least [CONFIDENTIAL TREATMENT REQUESTED] after the expiration date of the last
Batch manufactured by Catalytica. These rights of the Customer shall survive and
continue after termination or expiration. Catalytica shall permit the FDA or
other applicable governmental authorities access to such documents to the extent
permitted by law.

       (e)   Upon expiration or termination of this Agreement, the obligations
of confidentiality and restrictions on use of Confidential Information under
Article 13 hereof shall survive for the period provided therein.

       (f)   For a period of [CONFIDENTIAL TREATMENT REQUESTED] following
expiration or termination of this Agreement, Catalytica shall make available to
Customer for copying, from any drug and biologic master files, any
non-confidential information of Catalytica specific to the Product, and that can
be used by Customer to support any investigational studies or commercial
marketing of such Products previously manufactured, packaged, labeled, and
tested by Catalytica under this Agreement.

                                       19
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                                   ARTICLE 11
                                     CLAIMS

       11.1   CLAIMS. In the event that any of the Product shall fail to conform
with any warranty set forth herein relating to quality and/or the
Specifications, Customer shall reject such Product by giving written notice to
Catalytica not later than [CONFIDENTIAL TREATMENT REQUESTED] after Customer's
receipt of such Product and related documentation as set forth in the Quality
Agreement; any Product not rejected in accordance with the foregoing shall be
deemed accepted by Customer and conforming unless the Customer has conducted at
least one test on the applicable Batch of Product, or has requested in writing
within such [CONFIDENTIAL TREATMENT REQUESTED] additional time to perform
additional testing on the Product; which time shall not exceed an additional
[CONFIDENTIAL TREATMENT REQUESTED], or such longer time period as may be agreed
to by the Parties. Any notice given hereunder shall specify the manner in which
the Product fails to meet such warranty or the Specifications. Guidelines for
the resolution of disputed claims regarding conformity of a Batch of Products
are set forth in the Quality Agreement. [CONFIDENTIAL TREATMENT REQUESTED]. If
the nonconformity in properly rejected Product is otherwise caused by
Catalytica's negligence, omission or willful misconduct, Catalytica shall
[CONFIDENTIAL TREATMENT REQUESTED]. Notwithstanding the foregoing sentence, if
Catalytica's negligence or willful misconduct causes loss of IDEC Ingredients or
the [CONFIDENTIAL TREATMENT REQUESTED], Catalytica shall credit Customer's
account for the Acquisition Cost and all labor and other costs associated with
such IDEC Ingredients. If payment therefor has previously been made by Customer,
Catalytica shall, [CONFIDENTIAL TREATMENT REQUESTED].

       11.2   DISPOSITION OF NONCONFORMING PRODUCT. In any case where Customer
expects to make a claim against Catalytica with respect to damaged or otherwise
nonconforming Product, Customer shall not dispose of such Product without
written authorization and instructions of Catalytica either to dispose of the
Product or to return the Product to Catalytica. If the Product is returned to
Catalytica, all risk of loss and/or damage to such Product [CONFIDENTIAL
TREATMENT REQUESTED].

       11.3   PRODUCT HOLDS/REJECTS/CLAIMS. Catalytica shall notify Customer
[CONFIDENTIAL TREATMENT REQUESTED] of Product holds and/or rejects that have, or
are expected to have, an impact on the manufacturing process and that will
require, or are expected to require, Customer approval prior to resolution.
Catalytica shall provide Customer notice of any Third Party complaint of which
Catalytica receives notice. Such notification by Catalytica shall be in writing,
and shall include an explanation of or the reasons for such holds and/or
rejects.

                                       20
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                                   ARTICLE 12
                                 INDEMNIFICATION

       12.1   INDEMNIFICATION BY CUSTOMER. Customer shall indemnify, defend and
hold Catalytica, its Affiliates and their respective directors, officers,
employees, agents, successors and assigns harmless from and against any damages,
judgments, claims, suits, actions, liabilities, costs and expenses (including,
but not limited to, reasonable attorneys' fees) arising out of or connected with
Third Party claims relating to [CONFIDENTIAL TREATMENT REQUESTED].

       12.2   INDEMNIFICATION BY CATALYTICA. Except as otherwise provided in
Section 12.1 above, Catalytica shall indemnify, defend and hold Customer, its
Affiliates and their respective directors, officers, employees, agents,
successors and assigns harmless from and against any damages, judgments, claims,
suits, actions, liabilities, costs and expenses (including, but not limited to,
reasonable attorneys' fees) resulting [CONFIDENTIAL TREATMENT REQUESTED].

       12.3   INDEMNIFICATION PROCEDURES. A Party (the "Indemnitee") which
intends to claim indemnification under this Article 12 shall promptly notify the
other Party (the "Indemnitor") in writing of any action, claim or other matter
in respect of which the Indemnitee or any of its Affiliates, or any of their
respective directors, officers, employees or agents intend to claim such
indemnification; PROVIDED, HOWEVER, the failure to provide such notice within a
reasonable period of time shall not relieve the Indemnitor of any of its
obligations hereunder except to the extent the Indemnitor is prejudiced by such
failure. Prompt or reasonable notice shall depend on the nature of the claim
and/or the circumstances but shall normally be considered as ten (10) business
days from a Party's knowledge of such claim. The Indemnitee, its Affiliates, and
their respective directors, officers, employees and agents shall cooperate fully
with the Indemnitor and its legal representatives in the investigation,
negotiation, compromise, settlement and defense of any action, claim or other
matter covered by this indemnification. The Indemnitor shall be in charge of and
control of any such investigation, negotiation, compromise, settlement and
defense and shall have the right to select counsel with respect thereto,
provided that the Indemnitor shall promptly notify the Indemnitee of all
developments in the matter. In no event shall the Indemnitor or Indemnitee
compromise or settle any such matter without the prior written consent of the
other Party, which shall not be bound by any such compromise or settlement
absent its prior consent, which shall not be unreasonably withheld or delayed.
The Indemnitee shall have the right, but not the obligation, to be represented
by counsel of its own selection and at its own expense.

       12.4   SURVIVAL OF INDEMNIFICATION OBLIGATIONS. The provisions of this
Article 12 shall survive the expiration or termination of this Agreement.

                                       21
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

       12.5   LIMITATION OF LIABILITY AND CLAIMS. [CONFIDENTIAL TREATMENT
REQUESTED]

       12.6   INSURANCE. The Parties shall provide each other, on request,
documentation assuring that such Party maintains sufficient insurance coverage
in amounts reasonably satisfactory to the other Party consistent with industry
practices.

                                   ARTICLE 13
                                 CONFIDENTIALITY

       13.1   TREATMENT OF CONFIDENTIAL INFORMATION. Except as otherwise
provided in this Article 13, during the Initial Term of this Agreement,
including any renewals thereof, and for a period of [CONFIDENTIAL TREATMENT
REQUESTED] thereafter:

       (a)   Catalytica will retain in confidence, take reasonable efforts to
maintain the confidentiality of, and use only for purposes of this Agreement any
Confidential Information disclosed by Customer or on behalf of Customer to
Catalytica under this Agreement; and

       (b)   Customer will retain in confidence, take reasonable efforts to
maintain the confidentiality of, and use only for purposes of this Agreement any
Confidential Information disclosed by Catalytica or on behalf of Catalytica to
Customer under this Agreement.

       13.2   RIGHT TO DISCLOSE. To the extent it is reasonably necessary or
appropriate to fulfill its obligations or exercise its rights under this
Agreement or any rights which survive termination or expiration hereof, each
Party may disclose Confidential Information to its Affiliates, sublicensees,
consultants, outside contractors, clinical investigators or other Third Parties
on condition that such entities or persons agree in writing (a) to keep the
Confidential Information confidential for the same time periods and to the same
extent as each Party is required to keep the Confidential Information
confidential and (b) to use the Confidential Information only for such purposes
as such Party is entitled to use the Confidential Information. Each Party or its
Affiliates or sublicensees may disclose such Confidential Information to
government or other regulatory authorities to the extent that such disclosure
(i) is reasonably necessary to obtain patents or authorizations to conduct
clinical trials with and to market commercially the Product, provided such Party
is otherwise entitled to engage in such activities under this Agreement or (ii)
is otherwise legally required.

       13.3   TERMINATION OF CONFIDENTIALITY AGREEMENT. The Confidentiality
Agreement between the Parties dated March 10, 1998 is hereby terminated. All
Confidential Information disclosed by one Party to the other Party pursuant to
such Confidentiality Agreement shall be deemed to have been disclosed hereunder
and now subject to the terms and conditions of this Article 13.

                                       22
<Page>

                                                          CONFIDENTIAL TREATMENT

                                   ARTICLE 14
                              INTELLECTUAL PROPERTY

       14.1   CATALYTICA PROPERTY. Customer acknowledges that Catalytica
possesses certain inventions, processes, know-how, trade secrets, improvements,
other intellectual properties and other assets, including but not limited to
procedures and techniques, computer technical expertise, software, and certain
technical expertise and conceptual expertise in the area of drug processing and
manufacturing, which have been independently developed by Catalytica or its
Affiliates without the benefit of any information provided by Customer
(collectively "Catalytica Property"). Customer and Catalytica agree that any
Catalytica Property or improvements thereto which are used, improved, modified
or developed by Catalytica under or during the term of this Agreement are the
product of Catalytica's technical expertise possessed and developed by
Catalytica or its Affiliates prior to or during the performance of this
Agreement and are the sole and exclusive property of Catalytica or its
Affiliates, as the case may be.

       14.2   CUSTOMER PROPERTY. Catalytica acknowledges that Customer possesses
certain inventions, processes, know-how, trade secrets, improvements, other
intellectual properties and other assets, including but not limited to
procedures and techniques, computer technical expertise, software and certain
technical expertise and conceptual expertise in the area of drug development,
which have been independently developed by Customer or its Affiliates without
the benefit of any information provided by Catalytica (collectively "Customer
Property"). Customer and Catalytica agree that any Customer Property or
improvements thereto which are used, improved, modified or developed by Customer
or its Affiliates prior to or during the term of this Agreement are the sole and
exclusive property of Customer or its Affiliates, as the case may be.

       14.3   OWNERSHIP AND RIGHTS TO INVENTIONS AND TECHNOLOGY. Ownership of
all inventions, technology and information, whether patentable or not (other
than those described in Section 14.1, and 14.2 which shall be owned by
Catalytica and Customer, respectively), shall be as follows: owned by Customer,
if conceived, reduced to practice or created solely by Customer and/or its
agents during the performance of this Agreement; or (b) owned by Catalytica, if
conceived, reduced to practice or created solely by Catalytica and/or its agents
during the performance of this Agreement; provided, however, Catalytica shall
grant and hereby grants to Customer a royalty-free, non-exclusive, world-wide,
irrevocable license to practice any such Catalytica-owned technology to
manufacture the Product in Customer-owned or other facilities. If Catalytica's
efforts under this Agreement result in inventions which are jointly owned by
Catalytica and Customer because employees or agents for each of Catalytica and
Customer make inventive contributions thereto, that is employees or agents of
both Parties would be or are properly named as co-inventors under the laws of
the United States on any patent application claiming such inventions, then each
Party shall have full rights to exploit such jointly owned inventions for its
own commercial purposes without any obligation to the other Party. Catalytica
shall be responsible for the costs of filing, prosecution and maintenance for
patents and patent applications on Catalytica's owned technology and inventions
and the Parties shall share equally the patenting costs of any jointly owned
inventions. In this regard, any decision to file for patent coverage on jointly
owned inventions, shall be mutually agreed upon, and the Parties will select a
mutually acceptable patent counsel to file and prosecute applications based on
such joint inventions.

                                       23
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                                   ARTICLE 15
                                 FORCE MAJEURE

       15.1   EFFECTS OF FORCE MAJEURE. Except as expressly set forth below,
neither Party shall be held liable or responsible for failure or delay in
fulfilling or performing any of its obligations under this Agreement in case
such failure or delay is due to any condition beyond the reasonable control of
the affected Party including, without limitation, [CONFIDENTIAL TREATMENT
REQUESTED] (a "Force Majeure Event"). Notwithstanding the foregoing, Customer
shall be obligated hereunder to pay for Product received by Customer in
accordance with the terms hereof, including without limitation of time for
making any such payment. Except as provided below, such excuse shall continue as
long as the Force Majeure Event continues. Upon cessation of such Force Majeure
Event, such Party shall promptly resume performance hereunder; PROVIDED,
HOWEVER, if such Force Majeure Event continues for more than [CONFIDENTIAL
TREATMENT REQUESTED], Customer may at its election [CONFIDENTIAL TREATMENT
REQUESTED].

       15.2   NOTICE OF FORCE MAJEURE EVENT. In the event either Party is
delayed or rendered unable to perform due to a Force Majeure Event, the affected
Party shall give notice of the same and its expected duration to the other Party
promptly after the occurrence of the cause relied upon, and upon the giving of
such notice the obligations of the Party giving the notice will be suspended
during the continuance of the Force Majeure Event; provided, however, such Party
shall take commercially reasonable steps to remedy the Force Majeure Event with
all reasonable dispatch. The requirement that the Force Majeure Event be
remedied with all reasonable dispatch shall not require the settlement of
strikes or labor controversies by acceding to the demands of the opposing party.

                                   ARTICLE 16
                         LEGAL COMPLIANCE; AUTHORIZATION

       16.1   LEGAL COMPLIANCE. Each Party shall comply in all material respects
with all Applicable Laws and Regulations governing the conduct of its business
pursuant to this Agreement, including, but not limited to, the FD&C Act.

       16.2   AUTHORIZATION.

       (a)   Catalytica hereby represents and warrants to Customer that all
corporate action on the part of Catalytica and its officers and directors
necessary for the authorization, execution and delivery of this Agreement and
the performance of all obligations of Catalytica hereunder has been taken.

                                       24
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

       (b)   Customer hereby represents and warrants to Catalytica that all
requisite action on the part of Customer and its officers and directors
necessary for the authorization, execution and delivery of this Agreement and
the performance of all obligations of Customer hereunder has been taken.

                                   ARTICLE 17
                          PRESS RELEASES; USE OF NAMES

       17.1   PRESS RELEASES. Any press release, publicity or other form of
public written disclosure related to this Agreement prepared by one Party shall
be submitted to the other Party prior to release for approval, which approval
shall not be unreasonably withheld or delayed by such other Party.

       17.2   USE OF NAMES. Except as expressly provided or contemplated
hereunder and except as otherwise required by applicable law, no right is
granted pursuant to this Agreement to either Party to use in any manner the
trademarks or name of the other Party, or any other trade name, service mark, or
trademark owned by or licensed to the other Party in connection with the
performance of this Agreement. Neither Party shall disclose the existence and
terms of this Agreement except as may be required by applicable law.

                                   ARTICLE 18
                            DISPUTE RESOLUTION; VENUE

       18.1   EXCLUSIONS. Section 18.2 below shall not apply to any disputes
arising under Article 12 or Article 13 hereof.

       18.2   DISPUTE RESOLUTION. The Parties recognize that a BONA FIDE dispute
as to certain matters may from time to time arise during the term of this
Agreement which relates to either Party's rights and/or obligations hereunder.
In the event of the occurrence of such a dispute, either Party may, by notice to
the other Party, have such dispute referred to their respective officers
designated below, or their successors, for attempted resolution by good faith
negotiations within thirty (30) days after such notice is received. Such
designated officers are as follows:

       For Customer   - [CONFIDENTIAL TREATMENT REQUESTED]

       For Catalytica - [CONFIDENTIAL TREATMENT REQUESTED]

       In the event the designated officers are not able to resolve such dispute
within such thirty (30) day period, or such other period of time as the Parties
may mutually agree in writing, each Party shall have the right to pursue any and
all remedies available at law or in equity.

       18.3   VENUE. Any court proceeding initiated by one Party against the
other Party with respect to this Agreement shall be commenced in the United
States District Court for the Southern District of New York; PROVIDED, HOWEVER,
if the court proceeding is brought as a third party action as part of a pending
proceeding in a different venue, either Party may initiate such third party
action against the other Party in such other venue.

                                       25
<Page>

                                                          CONFIDENTIAL TREATMENT

                                   ARTICLE 19
                                  MISCELLANEOUS

       19.1   INDEPENDENT CONTRACTORS. The relationship between Customer and
Catalytica is that of independent contractors and nothing herein shall be deemed
to constitute the relationship of partners, joint venturers, nor of principal
and agent between Customer and Catalytica. Neither Party shall have any express
or implied right or authority to assume or create any obligations on behalf of
or in the name of the other Party or to bind the other Party to any contract,
agreement or undertaking with any Third Party.

       19.2   CUSTOMER ASSISTANCE. To assist Catalytica in its performance of
this Agreement, Customer shall provide Catalytica, in a timely fashion, with all
relevant information, documentation and data (including without limitation any
information, documentation and data relating to product safety and information,
documentation and data, including BLA numbers, NDC codes, etc., reasonably
requested by Catalytica and necessary for Catalytica to drug list the product)
which is necessary or appropriate for Catalytica's performance hereunder.
Customer shall cooperate with Catalytica in the performance of this Agreement
and shall deal honestly and in good faith with Catalytica.

       19.3   ASSIGNMENT; SUBCONTRACTORS. This Agreement may not be assigned or
otherwise transferred by either Party without the prior written consent of the
other Party; PROVIDED, HOWEVER, either Party may, without such consent, assign
this Agreement (a) in connection with the transfer or sale of all or
substantially all of the assets of such Party or the line of business of which
this Agreement forms a part, (b) in the event of the merger or consolidation of
a Party hereto with another company, or (c) to any Affiliate of the assigning
Party. Any purported assignment in violation of the preceding sentence shall be
void. Any permitted assignee shall assume all obligations of its assignor under
this Agreement. No assignment shall relieve either Party of responsibility for
the performance of any obligation which accrued prior to the effective date of
such assignment.

       19.4   CONTINUING OBLIGATIONS. Termination, assignment or expiration of
this Agreement shall not relieve either Party from full performance of any
obligations incurred prior thereto.

       19.5   WAIVER. Neither Party's waiver of any breach or failure to enforce
any of the terms and conditions of this Agreement, at any time, shall in any way
affect, limit or waive such Party's right thereafter to enforce and compel
strict compliance with every term and condition of this Agreement.

       19.6   SEVERABILITY. Each Party hereby expressly agrees that it has no
intention to violate any public policy, statutory or common laws, rules,
regulations, treaty or decision of any government agency or executive body
thereof of any country or community or association of countries; that if any
word, sentence, paragraph, clause or combination thereof in this Agreement is
found by a court or executive body with judicial powers having jurisdiction over
this Agreement or either Party hereto, in a final unappealed order, to be in
violation of any such provisions in any country or community or association of
countries, such words, sentences, paragraphs, clauses or combination shall be
inoperative in such country or community or association of countries and the
remainder of this Agreement shall remain binding upon the

                                       26
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

Parties, so long as enforcement of the remainder does not violate the Parties'
overall intentions in this transaction.

       19.7   HEADINGS. The headings in this Agreement are for convenience of
reference only and shall not affect its interpretation.

       19.8   CONSTRUCTION. This Agreement has been jointly prepared on the
basis of the mutual understanding of the Parties and shall not be construed
against either Party by reason of such Party's being the drafter hereof or
thereof.

       19.9   EXHIBITS, SCHEDULES AND ATTACHMENTS. Any and all exhibits,
schedules and attachments referred to herein form an integral part of this
Agreement and are incorporated into this Agreement by such reference.

       19.10   NOTICES. All notices and other communications required or
permitted to be given under this Agreement shall be in writing and shall be
delivered personally or sent by (a) registered or certified mail, return receipt
requested, (b) a nationally-recognized courier service guaranteeing next-day
delivery, charges prepaid or (c) facsimile (with the original promptly sent by
any of the foregoing manners), and shall be deemed to have been given upon
mailing or upon transmission by facsimile, as the case may be. Any such notices
shall be addressed to the receiving Party at such Party's address set forth
below, or at such other address as may from time to time be furnished by similar
notice by either Party:

       If to Catalytica:       Catalytica Pharmaceuticals, Inc.
                               Intersection US 13/NC 11 and US 264
                               Greenville, NC  27834
                               Attn: [CONFIDENTIAL TREATMENT REQUESTED]
                               Facsimile No.: [CONFIDENTIAL TREATMENT REQUESTED]

                               With a copy of legal notices to:
                               Company Secretary

                               Facsimile No.: [CONFIDENTIAL TREATMENT REQUESTED]

                                       27
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

       If to Customer:         IDEC Pharmaceuticals Corporation
                               3030 Callan Road
                               San Diego, CA  92121
                               Attn: [CONFIDENTIAL TREATMENT REQUESTED]
                               Facsimile No.: [CONFIDENTIAL TREATMENT REQUESTED]

                               With copies of legal notices to:
                               Company Secretary

                               Facsimile No.: [CONFIDENTIAL TREATMENT REQUESTED]

       19.11   COUNTERPARTS. This Agreement and any amendment or supplement
hereto may be executed in any number of counterparts and any Party hereto may
execute any such counterpart, each of which when executed and delivered shall be
deemed to be an original and all of which counterparts taken together shall
constitute but one and the same instrument. The execution of this Agreement and
any such amendment or supplement by any Party hereto will not become effective
until counterparts hereof have been executed by both Parties hereto.

       19.12   GOVERNING LAW; ENTIRE AGREEMENT. The validity, interpretation and
performance of this Agreement shall be governed and construed in accordance with
the laws of the State of New York without regard to the conflicts of laws
provisions thereof. This Agreement constitutes the full understanding of the
Parties and a complete and exclusive statement of the terms of their agreement.
No terms, conditions, understanding, or agreement purporting to modify or vary
the terms of this Agreement shall be binding unless hereafter made in writing
and signed by the Party to be bound. No modification to this Agreement shall be
effected by the acknowledgment or acceptance of any Purchase Order or shipping
instruction forms or similar documents containing terms or conditions at
variance with or in addition to those set forth herein.

       IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed
by their respective duly authorized representatives as of the day and year first
above written.

IDEC PHARMACEUTICALS CORPORATION     CATALYTICA PHARMACEUTICALS, INC.

By:  /s/ William H. Rohn             By:  /s/ Michael H. Thomas
     ---------------------------          ---------------------------

Title:  Chief Operations Officer     Title:  President & Chief Executive Officer
        ------------------------             -----------------------------------

Date:  August 8, 2001                Date:  August 8, 2001
       --------------                       --------------

                                       28
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                                    EXHIBIT 1

                       [CONFIDENTIAL TREATMENT REQUESTED]

                                       29
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                                    EXHIBIT 2

                      DRUG PRODUCT COMPONENT SPECIFICATIONS

                       [CONFIDENTIAL TREATMENT REQUESTED]

                                       30
<Page>

                                                          CONFIDENTIAL TREATMENT

                                    EXHIBIT 3

                            PACKAGING SPECIFICATIONS

                                       31
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                                   EXHIBIT 3A

                        Primary Packaging Specifications

                       [CONFIDENTIAL TREATMENT REQUESTED]

                                       32
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                                   EXHIBIT 3B

                       Secondary Packaging Specifications

                       [CONFIDENTIAL TREATMENT REQUESTED]

                                       33
<Page>

                                                          CONFIDENTIAL TREATMENT

                                    EXHIBIT 4

                             PRODUCT SPECIFICATIONS

                                       34
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                                    EXHIBIT 5

                                QUALITY AGREEMENT

                        [CONFIDENTIAL TREATMENT REQUESTED]

                                       35<Page>

CONFIDENTIAL TREATMENT REQUESTED                                   EXHIBIT 10.12

CONFIDENTIAL TREATMENT REQUESTED: PAGES WHERE CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED ARE MARKED "CONFIDENTIAL TREATMENT REQUESTED" AND APPROPRIATE
SECTIONS, WHERE TEXT HAS BEEN OMITTED, ARE NOTED WITH "[CONFIDENTIAL TREATMENT
REQUESTED]." AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION.

       This COLLABORATIVE DEVELOPMENT AGREEMENT ("CDA"), is made effective this
21st day of September, 2001 ("EFFECTIVE DATE"), between Mitsubishi-Tokyo
Pharmaceuticals, Inc., a company organized under Japanese law and having its
principal executive offices at 2-6, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
103-8405, Japan ("MTP") and IDEC Pharmaceuticals Corporation, a corporation
organized under the laws of the State of Delaware and having its principal
executive offices at 3030 Callan Road, San Diego, California 92121, USA
("IDEC").

                                   BACKGROUND

       WHEREAS, IDEC is engaged in research and development and has accumulated
considerable knowledge relating to antibody-based products directed against the
B7 cell function, and the use of such products for the palliation, evaluation,
diagnosis, treatment and/or prophylaxis of human disease states which are caused
or exacerbated by cells expressing the B7 (CD80) antigen;

       WHEREAS, MTP is interested in performing clinical development relating to
such antibody products;

       WHEREAS, Mitsubishi Kasei Corporation (a predecessor in interest to MTP)
and IDEC are parties to that certain License Agreement of November 11, 1993
("LICENSE AGREEMENT"), under which the Parties have granted the licenses set
forth under Section 2.04 (i)-(iv) of the LICENSE AGREEMENT, as further specified
therein;

       WHEREAS, Mitsubishi Kasei Corporation and IDEC where previously parties
to a certain Collaborative Development Agreement dated as of November 11, 1993
("CDA1"), as amended by that certain Memorandum of Understanding between the
parties dated December 11, 1996 ("MOU"), and that certain letter agreement of
December 13, 1996 ("LETTER AGREEMENT") (collectively "the ORIGINAL CDA
AGREEMENTS");

                                        1
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

       WHEREAS, IDEC has developed an anti-CD80 antibody (IDEC-114) and has
completed a Phase I/II clinical trial and has an ongoing Phase II clinical
trial, each studying the use of IDEC-114 in the treatment of psoriasis;

       WHEREAS, [CONFIDENTIAL TREATMENT REQUESTED]; and

       WHEREAS, both MTP and IDEC desire to renew their collaboration in the
further development of IDEC-114 for the treatment of psoriasis.

       NOW, THEREFORE, in consideration of the covenants and obligations
expressed herein, and intending to be legally bound, and otherwise to be bound
by proper and reasonable conduct, the PARTIES agree as follows:

                           ARTICLE I.   DEFINITIONS

1.01   "AFFILIATES" shall mean any corporation, firm, partnership or other
entity, whether de jure or de facto, which directly or indirectly owns, is owned
by or is under common ownership with a PARTY to this CDA to the extent of at
least fifty percent (50%) of the equity (or such lesser percentage which is the
maximum allowed to be owned by a foreign corporation in a particular
jurisdiction) having the power to vote on or direct the affairs of the entity
and any person, firm, partnership, corporation or other entity actually
controlled by, controlling or under common control with, a PARTY to this CDA.

1.02   "BLA" shall mean a Biologics License Application as contemplated by Title
42 U.S.C.S. Section 262, et seq. of the Public Health Service Act (PHSA) as
amended from time to time, filed by IDEC directed to use of the PRODUCT in the
FIELD.

1.03   "BEST EFFORTS" shall mean the maximum effort consistent with the
reasonable and prudent exercise of business judgment for a commercial
enterprise.

                                        2
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

1.04   "IDEC CDA DEVELOPMENT" shall mean the clinical development program and
any non-clinical investigation (other than manufacturing studies) on a PRODUCT
within the FIELD conducted during the term of this CDA or any extensions thereof
under Section 6.01, with the intent and purpose of generating data for
submission to a regulatory authority in the IDEC TERRITORY in support of an
application for governmental approval required for commercializing PRODUCT
within the FIELD. Such development plan shall be carried out in accordance with
ARTICLE 3, APPENDIX A and any non-clinical investigation deemed necessary by
IDEC to support IDEC CLINICAL TRIALS.

1.05   "MTP CDA DEVELOPMENT" shall mean the clinical development program on a
PRODUCT conducted during the term of this CDA or any extensions thereof under
Section 6.01, with the intent and purpose of generating data for submission to a
regulatory authority in the MTP TERRITORY in support of an application for
governmental approval required for commercializing PRODUCT within the FIELD.
Such development plan shall be carried out in accordance with ARTICLE 3,
APPENDIX B and any non-clinical investigation deemed necessary by MTP to support
MTP CLINICAL TRIALS.

1.06   "CDA DEVELOPMENT" shall mean IDEC CDA DEVELOPMENT and MTP CDA
DEVELOPMENT.

1.07   "CDA INFORMATION" shall mean any and all proprietary or confidential
data, know-how and results obtained from CDA DEVELOPMENT as further described in
ARTICLE 3 of this CDA, but shall not include any vectors or expression cassettes
discovered or created by either PARTY during the term of this CDA or CDA1.

1.08   "CLINICAL TRIAL" shall mean any PHASE I, PHASE I/II, PHASE II or PHASE
III CLINICAL TRIAL, conducted by either PARTY [CONFIDENTIAL TREATMENT
REQUESTED].

1.09   "FDA" shall mean the United States Food and Drug Administration.

1.10   [CONFIDENTIAL TREATMENT REQUESTED].

                                        3
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

1.11   "FIELD" shall mean use of the PRODUCT for in vivo treatment of psoriasis
in humans and in vitro diagnosis and evaluation of human tissue or fluid
relating to psoriasis.

1.12   [CONFIDENTIAL TREATMENT REQUESTED].

1.13   "IDEC TERRITORY" shall mean the entire world except the MTP TERRITORY.

1.14   "MITSUBISHI TECHNOLOGY" shall mean all MTP technology, know-how and
PATENTs which relates to PRODUCT, that MTP or its AFFILIATES owns or controls
either directly or indirectly, and to which MTP has the right to grant licenses
or sublicenses and developed during the term of this CDA or known to MTP as of
the EFFECTIVE DATE of this CDA, including, but not limited to, its antibody
technology, mammalian host-vector systems for high level expression of proteins,
manufacturing systems for GMP production of clinical grade antibodies, the
appropriate research samples of anti-murine B7 antibody(ies), cell lines
producing such antibodies, and pharmacological technology providing the
scientific basis for the clinical development of the PRODUCT, but shall not
include any vectors or expression cassettes discovered or created by either
PARTY during the term of this CDA.

1.15   "MTP TERRITORY" shall mean Japan, People's Republic of China, Hong Kong,
Republic of Korea, Singapore, Republic of China (Taiwan), Thailand, Indonesia,
Philippines, Malaysia, and all territories and possessions of such countries.

1.16   "PARTY" shall mean IDEC or MTP, as the case may be; "PARTIES" shall mean
IDEC and MTP.

1.17   "PATENTS" shall have the definition set forth in the LICENSE AGREEMENT.

1.18   "PHASE I CLINICAL TRIAL" shall mean a human clinical trial that is
intended to initially evaluate the safety and/or pharmacological effect of
PRODUCT in the FIELD in

                                        4
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

subjects or that would otherwise satisfy requirements of 21 CFR 312.21(a), or
its foreign equivalent. [CONFIDENTIAL TREATMENT REQUESTED].

1.19   "PHASE I/II CLINICAL TRIAL" shall mean a human clinical trial that is
intended to evaluate the safety and effectiveness of PRODUCT in the FIELD in
subjects or that would otherwise satisfy requirements of 21 CFR 312.21(a/b), or
its foreign equivalent. [CONFIDENTIAL TREATMENT REQUESTED].

1.20   "PHASE II CLINICAL TRIAL" shall mean a human clinical trial that is
intended to initially evaluate the effectiveness of PRODUCT in the FIELD in
subjects or that would otherwise satisfy requirements of 21 CFR 312.21(b), or
its foreign equivalent [CONFIDENTIAL TREATMENT REQUESTED].

1.21   "PHASE III CLINICAL TRIAL" shall mean a pivotal human clinical trial, the
results of which could be used to establish safety and efficacy of PRODUCT in
the FIELD as a basis for a BLA or that would otherwise satisfy requirements of
21 CFR 312.21(c), or its foreign equivalent [CONFIDENTIAL TREATMENT REQUESTED].

1.22   "PRODUCT" shall mean that certain antibody developed and owned by IDEC
that binds the human B7 (CD80) and is denominated IDEC-114.

1.23   "REAGENTS" shall mean cell lines expressing PRODUCT, including, but not
limited to transfected CHO cell lines expressing PRODUCT, and other compositions
of matter, such as, but not limited to those necessary or useful to develop or
produce PRODUCT, but shall expressly not include primers, Ig libraries, phages,
phagemids, plasmids, expression vectors or expression cassettes.

                                        5
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

1.24   "THIRD PARTY(IES)" shall mean any party other than a PARTY to this CDA or
an AFFILIATE of MTP or IDEC.

                      ARTICLE II.   CLINICAL DEVELOPMENT

2.01   Except as otherwise specifically provided herein, IDEC and MTP each shall
conduct any CDA DEVELOPMENT which such party undertakes in a scientific manner
in accordance with high scientific, medical and professional standards, and in
compliance in all material respects with all requirements of applicable laws,
rules and regulations and all applicable standard clinical practices to attempt
to achieve their objectives efficiently and expeditiously. The general terms
regarding the efforts to be undertaken in furtherance of CDA DEVELOPMENT,
including the objectives thereof, have been mutually agreed upon by the PARTIES,
and such agreement is incorporated upon the EFFECTIVE DATE within APPENDIX A of
this CDA and is a part thereof.

2.02   The principal scientists who will direct the respective responsibilities
of each PARTY are, for IDEC: [CONFIDENTIAL TREATMENT REQUESTED], and for MTP:
[CONFIDENTIAL TREATMENT REQUESTED] or such other principal scientist later
designated in writing by the relevant PARTY. All CDA INFORMATION disclosed
pursuant to this CDA, and all other communications concerning CDA DEVELOPMENT,
shall be directed to said principal scientists.

2.03   [CONFIDENTIAL TREATMENT REQUESTED]

2.04   MTP and IDEC each certifies that it is regularly engaged in conducting
clinical trials in vivo in humans, and that all biological materials and/or
chemicals provided by one PARTY to the other under this CDA shall be used in
compliance with all applicable laws and regulations.

                                        6
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

2.05   MTP shall have full scientific and management authority and
responsibility for the CDA DEVELOPMENT of PRODUCT within the MTP TERRITORY
including attainment and maintenance of regulatory approvals and price
registrations and shall have the right, from time to time as it sees fit, to
amend the MTP CDA activities set forth in Appendix B. All such activity shall be
undertaken [CONFIDENTIAL TREATMENT REQUESTED]. IDEC shall have full scientific
and management authority and responsibility for any CDA DEVELOPMENT of PRODUCT
in the IDEC TERRITORY and shall have the right, from time to time as it sees
fit, to amend the IDEC CDA activities set forth in Appendix A, subject to MTP's
rights under Section 6.02.

2.06   Except as otherwise specifically provided herein, the foregoing does not
imply a duty on the part of IDEC or MTP to complete or commence any CLINICAL
TRIAL or conduct any CDA DEVELOPMENT activities.

                ARTICLE III.   FUNDING OF CLINICAL DEVELOPMENT

3.01   In partial consideration for data generated by IDEC and provided to MTP
relating to IDEC's PHASE I/II CLINICAL TRIAL, and for ongoing development of the
PRODUCT, MTP shall make [CONFIDENTIAL TREATMENT REQUESTED].

3.02   MTP shall share in the funding of CDA DEVELOPMENT conducted by IDEC,
including past, ongoing and future CLINICAL TRIALS conducted by or on behalf of
IDEC, by making [CONFIDENTIAL TREATMENT REQUESTED] payments to IDEC as set forth
below.

   (a) [CONFIDENTIAL TREATMENT REQUESTED] after receipt of any invoice
       requesting payment, MTP shall make payment to IDEC in the amount of
       [CONFIDENTIAL TREATMENT REQUESTED].

                                        7
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

   (b) Notwithstanding (a) above, [CONFIDENTIAL TREATMENT REQUESTED].
   (c) Notwithstanding anything to the contrary herein, the obligation of MTP to
       make [CONFIDENTIAL TREATMENT REQUESTED].

3.03   MTP shall make the following [CONFIDENTIAL TREATMENT REQUESTED] MILESTONE
PAYMENTS [CONFIDENTIAL TREATMENT REQUESTED] to IDEC [CONFIDENTIAL TREATMENT
REQUESTED] after written notice is given to MTP that such milestone has been
achieved:

       [CONFIDENTIAL TREATMENT REQUESTED].

                                        8
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

[CONFIDENTIAL TREATMENT REQUESTED].

3.04   (a) (a) If applicable laws, rules or regulations require withholding of
income taxes or other taxes imposed upon INITIAL PAYMENTS and/or MILESTONE
PAYMENTS, the PARTIES [CONFIDENTIAL TREATMENT REQUESTED].

   (b) [CONFIDENTIAL TREATMENT REQUESTED].

          ARTICLE IV.   EXCHANGE OF INFORMATION AND CONFIDENTIALITY

4.01   The PARTIES acknowledge the value of a coordinated and uniformly applied
worldwide clinical development plan, especially as it relates to data reporting
and reporting of adverse events. Accordingly, each PARTY shall regularly report
to the other on the status and progress of its CLINICAL TRIAL efforts and as
further set forth in Section 4.02. Each PARTY agrees to prepare and exchange all
written reports in the English language. The exchange of such reports

                                        9
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

may be reasonably supplemented, at the request of the PARTY receiving a report,
by correspondence and/or visits to the other PARTY's facility.

4.02   Subject to the terms and conditions of this CDA, information
and data shall further be shared among the PARTIES as described below.
IDEC hereby grants to MTP a non-exclusive license in MTP TERRITORY,
[CONFIDENTIAL TREATMENT REQUESTED], to use such information and data
received from IDEC to research, develop, make, have made, use, import,
export, promote, market, offer for sale, sell and have sold the PRODUCT.

   (a) [CONFIDENTIAL TREATMENT REQUESTED]
   (b) [CONFIDENTIAL TREATMENT REQUESTED]
   (c) [CONFIDENTIAL TREATMENT REQUESTED]
   (d) [CONFIDENTIAL TREATMENT REQUESTED]
   (e) [CONFIDENTIAL TREATMENT REQUESTED]

                                        10
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

   (f) [CONFIDENTIAL TREATMENT REQUESTED]

4.03   During the term of the CDA, if IDEC enters into an agreement with a
THIRD PARTY under which IDEC grants such THIRD PARTY a license to make, have
made, use or sell any PRODUCT in the FIELD in any country in the IDEC
TERRITORY, [CONFIDENTIAL TREATMENT REQUESTED].

4.04   Each PARTY shall promptly report to the other PARTY any confirmed
information of serious or unexpected reactions or side effects related to the
utilization or medical administration of PRODUCT. In this regard, each PARTY
agrees that, throughout the duration of this CDA and thereafter, it will notify
the other PARTY immediately of any information concerning any PRODUCT or package
complaint, or any serious human adverse event, injury, toxicity or sensitivity
reaction or any unexpected incidence or severity thereof associated with the
clinical uses, studies, investigations, tests and marketing of PRODUCT, whether
or not determined to be attributable to PRODUCT. "Serious" as used in this
Section refers to experience which results in death, permanent or substantial
disability, in-patient hospitalization, prolongation of existing in-patient
hospitalization; or is a congenital anomaly or life threatening. "Unexpected" as
used in this Section refers to: (i) conditions or developments encountered
during preclinical or clinical studies which could be material to the successful
continuance of development of PRODUCT; (ii) conditions or developments not
encountered during clinical studies of PRODUCT; and (iii)

                                        11
<Page>

                                                          CONFIDENTIAL TREATMENT

conditions or developments occurring with greater frequency, severity or
specificity than shown by information previously submitted to governmental
agencies or encountered during clinical studies of PRODUCT. Each PARTY shall
also notify the other PARTY in a timely manner of any other adverse experience
(i.e., any unfavorable and unintended change in the structure (signs), function
(symptoms) or chemistry (laboratory data)) of the body temporally associated
with the use of PRODUCT, whether or not considered related thereto. The PARTIES
further agree to negotiate pharmacovigilance reporting requirements.

4.05   Each PARTY shall throughout the duration of this CDA and thereafter
immediately notify the other PARTY of any information it receives regarding any
threatened or pending action by any regulatory agency in any country of the
world which may affect the safety or efficacy claims of PRODUCT or the continued
development or marketing of PRODUCT. Upon receipt of any such information, each
PARTY may consult with the other PARTY in an effort to arrive at a mutually
acceptable procedure for taking appropriate action; provided, however, that
nothing contained herein shall be construed as restricting either PARTY's
ability to make a timely report of such matter to any governmental agency or
take other action that it deems to be appropriate or required by applicable law
or regulation.

4.06   The PARTIES agree throughout the duration of this CDA and for the
duration of marketing, by either PARTY, of any PRODUCT in the FIELD to maintain
records and otherwise establish procedures to assure compliance with all
regulatory, professional or other legal requirements which apply to the
development, promotion and marketing of PRODUCT.

4.07   Neither PARTY shall disclose the existence of or any terms or conditions
of this CDA to any THIRD PARTY, either in a press release or in any other
manner, without the prior written consent of the other PARTY; provided, however,
that (subject to any applicable THIRD PARTY rights, obligations or restrictions)
a PARTY may disclose the terms or conditions of this CDA (a) on a need-to-know
and confidential basis to its professional legal and financial advisors to the
extent such disclosure is reasonably necessary, and (b) to a THIRD PARTY in
connection with (i) an equity investment in a PARTY to this CDA, (ii) a merger,
consolidation or similar transaction by a PARTY to this CDA, or (iii) the sale
of all or substantially all of the assets of a

                                       12
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

PARTY to this CDA, provided that all of the foregoing shall be subject to
confidentiality and non-use obligations imposed by this CDA and the LICENSE
AGREEMENT.

4.08   The PARTIES agree that the formal initiation or early termination of this
collaboration as evidenced by the terms of this CDA may constitute "material
information" for the PARTIES that must be disclosed to the public and the
PARTY's shareholders via a press release. Such a press release shall be prepared
by the other PARTY and reviewed in good faith and approved by the other PARTY
concurrently with the review and approval of this CDA or early termination
thereof.

4.09   Notwithstanding the foregoing, no public announcement or other disclosure
to THIRD PARTIES concerning the terms of this CDA shall be made, either directly
or indirectly, by either PARTY to this CDA, except as may be legally required,
without first obtaining the written approval of the other PARTY and agreement
upon the nature of such announcement or disclosure, provided that such approval
shall not be unreasonably withheld. The PARTY desiring to make any such public
announcement or other disclosure shall use BEST EFFORTS to inform the other
PARTY of the proposed announcement or disclosure in reasonably sufficient time
prior to public release, and shall use BEST EFFORTS to provide the other PARTY
with a written copy thereof, in order to allow such other PARTY to comment upon
such announcement or disclosure.

4.10   Neither MTP nor IDEC shall submit for written publication any manuscript
abstract or the like, or make any oral presentation, which includes data or
other information generated or provided by the other PARTY in the course of, or
otherwise as a result of, CDA DEVELOPMENT or otherwise related to PRODUCT,
without first obtaining the prior written consent of such other PARTY, which
consent shall not be unreasonably withheld. The contribution of each PARTY shall
be noted in all publications or presentations by acknowledgment or
co-authorship, whichever is appropriate.

4.11   Neither MTP nor IDEC may, during the term of this CDA [CONFIDENTIAL
TREATMENT REQUESTED], disclose or reveal to THIRD PARTIES any CDA INFORMATION
received from the other PARTY or otherwise developed by either PARTY in the
performance of activities in furtherance of this

                                       13
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

CDA, except that such other PARTY may use or disclose such confidential
information (i) for the purposes of investigating, developing, manufacturing,
marketing or seeking partners for PRODUCT, provided that prior to any such
disclosure such potential partners are bound to at least as stringent
confidentiality obligations as set forth herein, (ii) for securing essential or
desirable authorizations, privileges or rights from governmental agencies, (iii)
if required to be disclosed to a governmental agency, or (iv) is necessary to
file or prosecute patent applications concerning PRODUCT or to carry out any
litigation concerning PRODUCT. This confidentiality obligation shall not apply
to such information which is or becomes a matter of public knowledge, or came or
comes into the possession of the receiving PARTY independently of this CDA or
the LICENSE AGREEMENT (unless otherwise disclosed confidentially at any time by
MTP to IDEC or IDEC to MTP), or is disclosed to the receiving PARTY by a THIRD
PARTY having the right to do so, or is subsequently and independently developed
by employees of the receiving PARTY or AFFILIATES thereof who had no knowledge
of the CDA INFORMATION disclosed and can be so demonstrated by competent proof.
The PARTIES shall take reasonable measures to ensure that no unauthorized use or
disclosure is made by others to whom access to CDA INFORMATION is granted.

4.12   Subject to the terms of the LICENSE AGREEMENT, nothing in this CDA shall
be construed as preventing or in any way inhibiting either PARTY from complying
with statutory and regulatory requirements governing the manufacture, use and
sale or other distribution of PRODUCT in any manner it reasonably deems
appropriate, including, for example, by disclosing to regulatory authorities
confidential or other information received from each other or THIRD PARTIES.

                         ARTICLE V.   PRODUCT SUPPLY

5.01   IDEC shall use its BEST EFFORTS to manufacture and supply to MTP,
[CONFIDENTIAL TREATMENT REQUESTED], PRODUCT manufactured under Good
Manufacturing Practice guidelines solely for the purpose of conducting CLINICAL
TRIALS in the MTP TERRITORY, as follows: [CONFIDENTIAL TREATMENT REQUESTED].

                                       14
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

If MTP desires vialed PRODUCT for conducting PHASE II CLINICAL TRIALS, MTP must
provide a firm order [CONFIDENTIAL TREATMENT REQUESTED] prior to delivery of
such vialed PRODUCT by IDEC to MTP. In any event, the amount of product
requested by MTP must be reasonably related to requirements for conducting such
studies under the appropriate protocols. IDEC shall establish cell lines,
manufacture and set specifications in accordance with applicable FDA and KOROSHO
(the Japanese Ministry of Health, Labor and Welfare) guidelines; however, if
additional development expense is required to meet KOROSHO`s guidelines,
[CONFIDENTIAL TREATMENT REQUESTED]. The obligations of IDEC under this Section
shall be suspended upon provision by IDEC to MTP of notice to terminate under
Section 6.04. The details of PRODUCT supply defined above, including
formulations of the PRODUCT like formulated bulk form or vialed Product, shall
be determined in any SUPPLY AGREEMENT between the PARTIES separately.

5.02   [CONFIDENTIAL TREATMENT REQUESTED]

                      ARTICLE VI.   TERM AND TERMINATION

6.01   This CDA shall come into effect on the EFFECTIVE DATE and, unless earlier
terminated hereunder, shall continue to be in effect [CONFIDENTIAL TREATMENT
REQUESTED]. If continued research or development is desirable, the collaboration
may be extended by mutual agreement between the PARTIES on reasonable terms and
conditions to be negotiated in good faith.

                                       15
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

6.02   MTP shall have the right to terminate this CDA [CONFIDENTIAL TREATMENT
REQUESTED].

6.03   IDEC shall have the right to terminate this CDA [CONFIDENTIAL TREATMENT
REQUESTED]. In such case, IDEC shall provide MTP with all data obtained by IDEC
prior to the termination and all reports written based on such data.

6.04   Either PARTY shall have the right to terminate this CDA if the other
PARTY materially fails or neglects to perform its obligation set forth in this
CDA and if such default is not cured [CONFIDENTIAL TREATMENT REQUESTED] after
receiving written request to cure such default from the other PARTY, such other
PARTY shall have the right to terminate this CDA by giving written notice to the
PARTY in default, provided the request to cure is given [CONFIDENTIAL TREATMENT
REQUESTED].

6.05   If not earlier terminated, this CDA shall automatically terminate upon
termination of the LICENSE AGREEMENT.

              ARTICLE VII.   RIGHTS AND DUTIES UPON TERMINATION

7.01   Upon expiration or termination of this CDA by either PARTY under any
section of ARTICLE 6 hereof, unless otherwise expressly provided herein,

   (a) [CONFIDENTIAL TREATMENT REQUESTED]

   (b) [CONFIDENTIAL TREATMENT REQUESTED]

                                       16
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

   (c) [CONFIDENTIAL TREATMENT REQUESTED]

   (d) all other obligations and provisions of this CDA shall terminate except

       (i)   the following which shall survive such termination: Sections 2.04,
             4.04, 4.05, 4.06, 4.07, 4.08, 4.10, 4.11, 5.02 and Articles 7, 8,
             10 through 16; and

       (ii)  in the case of expiration of this CDA, termination of this CDA
             under Section 6.02 or 6.03 or termination of this CDA by MTP under
             Section 6.04, the following which shall survive such expiration or
             termination: the license grant only of Section 4.02, but NOT IDEC's
             obligations to provide data or information which MTP does not have
             the right to receive at the time of such expiration or termination
             (e.g., BLA dossier).

7.02   All rights to terminate, and rights upon termination, provided for either
PARTY in this CDA are in addition to other remedies in law or equity which may
be available to either PARTY.

                 ARTICLE VIII.   WARRANTIES, REPRESENTATIONS,
                         INSURANCE AND INDEMNIFICATIONS

8.01   NOTHING IN THIS CDA SHALL BE CONSTRUED AS A WARRANTY THAT PATENTS ARE
VALID OR ENFORCEABLE OR THAT THEIR EXERCISE DOES NOT INFRINGE ANY VALID PATENT
RIGHTS OF THIRD PARTIES. A holding of invalidity or unenforceability of any
PATENT, from which no further appeal is or can be taken, shall not affect any
obligation already accrued hereunder.

8.02   MTP shall defend, indemnify and hold harmless IDEC, its officers,
directors, shareholders, employees, successors and assigns from (i) any and all
losses, damages, liabilities and expenses, including reasonable attorneys' fees,
resulting from any claim, complaint, suit, proceeding or cause of action against
any of them alleging physical or other injury, including death, brought by or on
behalf of an injured party, and (ii) loss of service or consortium or a similar
such claim, complaint, suit, proceeding or cause of action brought by a friend,
spouse, relative or companion of an injured party, due to such physical injury
or death and arising out of the administration, utilization and/or ingestion of
PRODUCT used or otherwise provided, directly or indirectly, to the injured party
by MTP (or any sublicensee of MTP), except to the

                                       17
<Page>

                                                          CONFIDENTIAL TREATMENT

extent such damages, claims, costs, losses, liabilities or expenses are caused
solely by IDEC's gross negligence or willful misconduct of any employee or agent
of IDEC and provided:

   (a) MTP shall have no obligation under this Section, unless (i) IDEC gives
       MTP prompt written notice of any claim or lawsuit or other action for
       which it seeks to be indemnified under this CDA, and (ii) MTP is granted
       full authority and control over the defense, including settlement,
       against such claim or lawsuit or other action, provided, however, that
       MTP may not enter into any settlement or other agreement that would
       materially limit the scope of any claim of IDEC's PATENTS, as defined in
       the LICENSE AGREEMENT without the prior written consent of IDEC, which
       consent shall not be unreasonably withheld or delayed; and

   (b) IDEC shall have the right to participate in the defense of any such
       claim, complaint, suit, proceeding or cause of action referred to in this
       Section utilizing attorneys of its choice, provided, however, except as
       provided in subsection (a) above, that MTP shall have final authority to
       handle any such claim, complaint, suit, proceeding or cause of action,
       including any settlement or other disposition thereof, for which IDEC
       seeks indemnification under this Section.

8.03   IDEC shall defend, indemnify and hold harmless MTP, its officers,
directors, shareholders, employees, successors and assigns from (i) any and all
losses, damages, liabilities and expenses, including reasonable attorneys' fees,
resulting from any claim, complaint, suit, proceeding or cause of action against
any of them alleging physical or other injury, including death, brought by or on
behalf of an injured party, and (ii) loss of service or consortium or a similar
such claim, complaint, suit, proceeding or cause of action brought by a friend,
spouse, relative or companion of an injured party, due to such physical injury
or death and arising out of the administration, utilization and/or ingestion of
PRODUCT used or otherwise provided, directly or indirectly, to the injured party
by IDEC (or any licensee of IDEC other than MTP), except to the extent such
damages, claims, costs, losses, liabilities or expenses are caused solely by
MTP's gross negligence or willful misconduct of any employee or agent of MTP and
provided:

                                       18
<Page>

                                                         CONFIDENTIAL TREATMENT

   (a) IDEC shall have no obligation under this Section, unless (i) MTP gives
       IDEC prompt written notice of any claim or lawsuit or other action for
       which it seeks to be indemnified under this CDA, and (ii) IDEC is granted
       full authority and control over the defense, including settlement,
       against such claim or lawsuit or other action, provided, however, that
       IDEC may not enter into any settlement or other agreement that would
       materially limit the scope of any claim of MTP's PATENTS, as defined in
       the LICENSE AGREEMENT without the prior written consent of MTP, which
       consent shall not be unreasonably withheld or delayed; and

   (b) MTP shall have the right to participate in the defense of any such claim,
       complaint, suit, proceeding or cause of action referred to in this
       Section utilizing attorneys of its choice, provided, however, except as
       provided in subsection (a) above, that IDEC shall have final authority to
       handle any such claim, complaint, suit, proceeding or cause of action,
       including any settlement or other disposition thereof, for which MTP
       seeks indemnification under this Section.

8.04   IDEC shall defend, indemnify and hold harmless MTP and its officers,
directors, shareholders, employees, successors and assigns from and against any
and all damages, claims, costs, losses, liabilities or expenses (including
reasonable attorneys' fees) arising out of, or resulting from or in connection
with IDEC's activities under this CDA, including, but not limited to, IDEC's
activities related to CDA DEVELOPMENT, IDEC's transfer of CDA INFORMATION to
MTP, any breach of a representation or warranty made to MTP by IDEC under this
CDA, except such damages, claims, costs, losses, liabilities or expenses which
are directly and proximately caused by MTP's gross negligence, provided MTP
shall have the right to participate (at its own cost) in the defense of any such
claim, complaint, suit, proceeding or cause of action referred to in this
Section utilizing attorneys of its choice, provided, however, that IDEC shall
have full authority and control to handle any such claim, complaint, suit,
proceeding or cause of action, including any settlement or other disposition
thereof, for which MTP seeks indemnification under this Section.

8.05   MTP shall defend, indemnify and hold harmless IDEC and its officers,
directors, shareholders, employees, successors and assigns from and against any
and all damages, claims, costs, losses liabilities or expenses (including
reasonable attorneys' fees) arising out of, or

                                       19
<Page>

                                                         CONFIDENTIAL TREATMENT

resulting from or in connection with MTP's activities under this CDA, including,
but not limited, to MTP's activities related to CDA DEVELOPMENT, or any breach
of a representation or warranty made to MTP by IDEC under this CDA, except such
damages, claims, costs, losses, liabilities or expenses which are directly and
proximately caused solely by IDEC's gross negligence, provided IDEC shall have
the right to participate (at its own cost) in the defense of any such claim,
complaint, suit, proceeding or cause of action referred to in this Section
utilizing attorneys of its choice, provided, however, that MTP shall have full
authority and control to handle any such claim, complaint, suit, proceeding or
cause of action, including any settlement or other disposition thereof, for
which IDEC seeks indemnification under this Section.

8.06   Except for a breach of Section 4.11 of this CDA, notwithstanding anything
else in this CDA, the LICENSE AGREEMENT or otherwise, neither PARTY will be
liable with respect to any subject matter of this CDA under any contract,
negligence, strict liability or other legal or equitable theory for any amounts
in excess in the aggregate of the amounts received by IDEC under this CDA and
the LICENSE AGREEMENT, for any incidental or consequential damages, or for cost
of procurement of substitute goods, technology, or services.

                         ARTICLE IX.   FORCE MAJEURE

9.01   If the performance of any part of this CDA by either PARTY, or of any
obligation under this CDA, is prevented, restricted, interfered with or delayed
by reason of any cause beyond the reasonable control of the PARTY liable to
perform, unless conclusive evidence to the contrary is provided, the PARTY so
affected shall, upon giving written notice to the other PARTY, be excused from
such performance to the extent of such prevention, restriction, interference or
delay, provided that the affected PARTY shall use its BEST EFFORTS to avoid or
remove such causes of non-performance and shall continue performance with the
utmost dispatch whenever such causes are removed. When such circumstances arise,
the PARTIES shall discuss what, if any, modification of the terms of this CDA
may be required in order to arrive at an equitable solution.

                                       20
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                          ARTICLE X.   GOVERNING LAW

10.01   This CDA shall be deemed to have been made in the State of California,
U.S.A. and its form, execution, validity, construction and effect shall be
determined in accordance with the laws of the State of California, U.S.A. as it
is applied to contracts entered into in the State of California between
California residents.

                          ARTICLE XI.   ARBITRATION

11.01   Any dispute, controversy or claim (except as to any issue relating to
intellectual property owned in whole or in part by IDEC) arising out of or
relating to this CDA, or the breach, termination, or invalidity thereof, shall
be settled by arbitration in accordance with the Commercial Arbitration Rules of
the American Arbitration Association, except as modified by this Section 11.01.
The number of arbitrators shall be [CONFIDENTIAL TREATMENT REQUESTED]. The
arbitration decision shall be binding and not be appealable to any court in any
jurisdiction. The prevailing PARTY may enter such decision in any court having
competent jurisdiction. The arbitration proceeding shall be conducted in the
English language in San Francisco, CA, unless the PARTIES agree in writing to
conduct the arbitration in another location.

11.02   Notwithstanding anything contained in Section 11.01 to the contrary, the
PARTIES shall have the right to institute judicial proceedings against the other
PARTY or anyone acting through or under the control of the other PARTY in order
to enforce the instituting PARTIES rights hereunder through reformation of
contract, specific performance, injunction, or similar equitable relief.

                         ARTICLE XII.   SEVARABILITY

12.01   In the event any portion of this CDA shall be held illegal, void or
ineffective, the remaining portions hereof shall remain in full force and
effect.

12.02   If any of the terms or provisions of this CDA are in conflict with any
applicable United States or California statute or rule of law, then such terms
or provisions shall be deemed inoperative to the extent that they may conflict
therewith and shall be deemed to be modified to conform with such statute or
rule of law.

                                       21
<Page>

                                                          CONFIDENTIAL TREATMENT

12.03   In the event that the terms and conditions of this CDA are materially
altered as a result of Sections 12.01 or 12.02, the PARTIES will renegotiate the
terms and conditions of this CDA to resolve any inequities.

                                ENTIRE AGREEMENT

12.04   This CDA, together with the LICENSE AGREEMENT, constitutes the entire
agreement between the PARTIES relating to the subject matter hereof, and
supersedes all previous writings and understandings in the ORIGINAL CDA
AGREEMENTS. No terms or provisions of this CDA shall be varied or modified by
any prior or subsequent statement, conduct or act of either of the PARTIES,
except that the PARTIES may amend this CDA by written instruments specifically
referring to and executed in the same manner as this CDA.

                           ARTICLE XIII.   PRIMACY

13.01   To the extent that any provision of this CDA conflicts with any
provision of any other agreement between the parties, the terms of this CDA
shall control.

                            ARTICLE XIV.   NOTICES

14.01   Any notice required or permitted under this CDA shall be sent by
certified mail or overnight courier service, postage pre-paid to the following
addresses of the PARTIES:

IDEC PHARMACEUTICALS CORPORATION
3030 Callan Road
San Diego, California  92121 U.S.A.
Attention:  Corporate Secretary

Copy to: President

MITSUBISHI-TOKYO PHARMACEUTICALS, INC.
2-6, Nihonbashi-Honcho 2-chome
Chuo-ku, Tokyo 103-84050 Japan

Attention:  General Manager, Licensing Department
Copy to:  General Manager of Preclinical Development Department; and General
Manager of Intellectual Property Department

14.02   Any notice required or permitted to be given concerning this CDA shall
be effective upon receipt by the PARTY to whom it is addressed.

                                       22
<Page>

                                                         CONFIDENTIAL TREATMENT

                           ARTICLE XV.   ASSIGNMENT

15.01   This CDA and the licenses herein granted shall be binding upon and inure
to the benefit of the successors in interest of the respective PARTIES. Neither
this CDA nor any interest hereunder shall be assignable by either PARTY without
the written consent of the other; provided, however, that IDEC may assign this
CDA or any PATENT owned by it to any AFFILIATE or to any corporation with which
it may merge or consolidate, or to which it may transfer all or substantially
all of its assets to which this CDA relates, without obtaining the consent of
the other PARTY.

                          ARTICLE XVI.   RECORDATION

16.01   The PARTIES shall have the right, at any time during the term of this
CDA, to record, register, or otherwise notify this CDA in any patent office or
other appropriate facility anywhere in the TERRITORY, and the PARTIES shall
provide reasonable assistance to each other in effecting such recording.

                            EXECUTION IN COUNTERPARTS

16.02   This CDA may be executed in any number of counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and
the same instrument.

   (a) IN WITNESS WHEREOF, the PARTIES, through their authorized officers, have
       executed this CDA.

MITSUBISHI-TOKYO PHARMACEUTICALS, INC.

By:  /s/ Ryuichi Tomizawa
     --------------------------

Name: Ryuichi Tomizawa

Title: President

Date:
       ------------------------

                                       23
<Page>

                                                         CONFIDENTIAL TREATMENT

ATTESTED:

By:  /s/ Akihiro Tobe
     --------------------------

Name: Akihiro Tobe

Title: President of Research and Development Division

Date:
       ------------------------

IDEC PHARMACEUTICALS CORPORATION

By:  /s/ William R. Rohn
     --------------------------

William R. Rohn

Title: Chief Operating Officer
       ------------------------
Date:
       ------------------------

                                       24
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                       COLLABORATIVE DEVELOPMENT AGREEMENT
                   MITSUBISHI-TOKYO PHARMACEUTICALS, INC.-IDEC
                           PHARMACEUTICALS CORPORATION
               APPENDIX A--CLINICAL PLAN FOR IDEC CDA DEVELOPMENT

                       [CONFIDENTIAL TREATMENT REQUESTED]

                                       25
<Page>

                                                CONFIDENTIAL TREATMENT REQUESTED

                       COLLABORATIVE DEVELOPMENT AGREEMENT
                   MITSUBISHI-TOKYO PHARMACEUTICALS, INC.-IDEC
                           PHARMACEUTICALS CORPORATION
                APPENDIX B--CLINICAL PLAN FOR MTP CDA DEVELOPMENT

                       [CONFIDENTIAL TREATMENT REQUESTED]

                                       26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]